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Chapter 1. Cell surface markers of cancer stem cells: diagnostic macromolecules 
and targets for drug delivery 
1.1 Introduction 
Cancer stem cells (CSCs), also known as tumor-propagating cells or tumor-
initiating cells, are subpopulations of undifferentiated, highly tumorigenic cells found 
within bulk tumors. CSCs have the ability to self
-
renew, differentiate, and generate a 
phenotype-identical copy of the tumor from which they were isolated upon implantation 
in a recipient animal (Fig. 1). Accordingly, CSCs reside at the apex of the tumor cell 
hierarchy and can differentiate into all of the cell types that comprise the host tumor.
1-8
 
CSC theory directly challenges the traditional stochastic model of cancer cell growth 
that predicts that all cells from a tumor have tumorigenic potential.
9
  
The development of suitable technologies to isolate CSCs from tumors (e.g., 
monoclonal antibodies of unique CSC surface macromolecules coupled with 
fluorescence-activated cell sorting (FACS) techniques) and appropriate animal models 
for xenotransplantation assays of isolated cell populations (e.g., non-obese diabetic, 
severe combined immuno-deficient (NOD/SCID) mice) have facilitated the 
identification of CSC populations from a variety of blood and solid tumors. 
3
 These 
technological advancements were prerequisite to the discovery of CSCs in acute 
myelogenous leukemia (AML), which is arguably the prototypical human cancer 
bearing an established CSC hierarchy. Seminal work by John Dick and colleagues 
provided the first critical evidence for CSCs by isolating (with FACS) the CD34
+
/CD38
−
 
fraction of human donor AML cells and engrafting those cells into severe combined 
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immunodeficient (SCID) mice.
9,10
 Engrafted cells were able to proliferate and 
differentiate, resulting in identical disease to that of the donor. Isolation of the AML 
CSC population (CD34
+
/CD38
−
) from the recipient mouse, followed by serial 
transplantation into a secondary recipient mouse yielded the same disease, thereby 
demonstrating the self-renewal properties of the initially engrafted CD34
+
/CD38
−
 AML 
cell fraction. This pioneering study provided insight into the long-standing observation 
that AML cells have only limited proliferative capacity by supporting the hypothesis that 
a rare leukemic clone must maintain the AML population.
11-13
 Additionally, this work 
provided crucial evidence for the hierarchical model of tumor heterogeneity by 
demonstrating that some populations of leukemic cells (CD34
+
/CD38
−
) exhibited CSC 
activity, whereas other leukemic cell populations (e.g., CD34
+
/CD38
+
 and CD34
−
) did 
not.
10
 The feature that only a sub
-
population of cells from a tumor can facilitate 
tumorigenesis is a tenant of the hierarchical model of tumor cell growth.
3,10
 AML CSCs 
exclusively give rise to clinical AML.
9,10
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Fig. 1.1 Depiction of the properties that are characteristic of cancer stem cells 
(CSCs). A. CSCs (shown in gray) can self-renew and undergo multi-lineage 
differentiation (cells in color). B. Tumorigenicity. CSCs are more tumorigenic than 
differentiated bulk tumor cells. 
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 Cancer therapies that are resisted by the CSC population are predicted to fail by 
the CSC model.
6,7
 Although outside the focus of this review, the drug resistance 
properties of CSCs may result due to increased cell quiescence,
14,15
 expression of anti-
apoptotic proteins,
16
 and upregulation of ABC multidrug resistance transporter 
proteins.
16,17
 The CSC hypothesis is also supported by clinical data. In the case of AML, 
approximately 44,000 new cases of AML are diagnosed annually in the United States, 
and 5-year survival rates are only 24%.
18
 Front-line small molecule treatments for AML 
include nucleoside analogues (e.g., cytarabine) and anthracyclines (e.g., idarubicin, 
daunorubicin), which are designed to induce apoptosis in rapidly dividing cancer 
cells.
19,20
 AML CSCs, which are largely quiescent, are typically resistant to standard 
chemotherapeutic agents. Furthermore, recent data have demonstrated that cytarabine 
actually facilitates AML CSC entry into G0/G1 phase, thereby promoting cell cycle 
quiescence and providing a mechanism that allows AML CSCs to survive 
chemotherapy.
21
 Consequently, viable strategies to eradicate CSC populations are 
clearly needed if curative cancer therapies are to be developed. A realized example of 
this concern has been documented with patients receiving the targeted bcr-abl tyrosine 
kinase antagonist imatinib (Gleevec®) for chronic myelogenous leukemia (CML). 
Although imatinib effectively converts CML into a chronically managed disease,
22,23
 a 
patient withdrawing from imatinib treatment  will ultimately exhibit disease relapse 
because imatinib does not eliminate CML CSCs.
24,25
 
 Elucidation of the molecular differences between differentiated cancer cells with 
high proliferation rates and nondifferentiated CSCs that are mostly quiescent is an 
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intense area of ongoing research.
3,26-28
 Equally important is the need to characterize 
those chemical features that confer cancerous versus non-cancerous stem cells (e.g., the 
differences in biochemistry between a leukemic stem cell and a normal hematopoietic 
stem cell).
3
 A variety of cytosolic and cell surface macromolecules have been 
characterized as diagnostic markers for the identification of CSCs from differentiated 
cancer cells, normal stem cells, or other cells from tissue. Many of these markers are 
utilized in combination for characterization of the CSC population (e.g., CD34
+
/ CD38
−
 
for AML CSCs described above).
10
 However, for isolation and drug targeting of CSCs, 
surface markers have proven to be more useful.
29-32
 Cell surface macromolecules are 
readily captured by magnetic micro-bead isolation techniques and are easily detected by 
flow cytometry, and the unique ligands presented on the cell surface offer receptors for 
targeted drug delivery.
33
 In this chapter, we have consolidated the known CSC cell 
surface markers that have been described for various blood and solid tumors into one 
document. Since intracellular markers for CSCs have been described and reviewed 
elsewhere,
30,34
 we have focused this review only on well-characterized cell surface 
markers due to their ability to serve as mediators for drug delivery into CSCs. In 
addition to compiling CSC surface markers, we review the unique chemical and 
structural features of the most well-known CSC surface markers and report recent efforts 
to deliver therapeutic agents into CSCs mediated by CSC specific cell surface 
macromolecules. Compendium of cell surface markers for identification of cancer stem 
cells summarized herein is the current knowledge of CSC markers from the following 
human cancers: leukemias (Table 1.1-1.3), breast (Table 1.4), colorectal (Table 1.5), 
  6 
liver (Table 1.6), pancreatic (Table 1.7), prostate (Table 1.8), melanoma (Table 1.9), 
brain (Table 1.10), bladder (Table 1.11), lung (Table 1.12), and ovarian carcinomas 
(Table 1.13). Recent efforts to deliver therapeutic molecules to CSCs are described in 
Table 1.14. Table 1.15 provides a compendium of the other commonly used names of 
the CSC markers discussed in the following sections. 
 
1.2 Cancer Stem Cells Found in Liquid Tumors 
1.2.1 Leukemia 
Leukemia is a family of diseases, comprised of blood, bone marrow, or lymphoid 
system cancers that are characterized by abnormal increases in white blood cell count.
35
 
In 2011, more than 44,000 children and adults in the United States were expected to 
develop some form of leukemia, and approximately 22,000 deaths were projected.
18,36,37
 
In 1994, Dick and coworkers first characterized the acute myelogenous leukemia stem 
cell population utilizing the CD34
+
/CD38
−
 cell surface marker combination.
10
 This 
landmark discovery catalyzed the search for CSC populations from related blood as well 
as solid tumors. The repertoire of CSC markers in leukemia is complicated and variable 
depending on leukemia subtype and stage of disease.
38
  
 
1.2.1.1 Acute myelogenous leukemia (AML) 
As has been introduced above, CD34
+/CD38− (Table 1.1) is the earliest 
documented stem cell marker combination in cancer and is still widely used to identify 
leukemic CSCs. In a seminal study, Dick and coworkers demonstrated that a small 
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subpopulation of AML cells with the CD34
+
/CD38
−
 cell surface phenotype was capable 
of producing a large number of colony
-
forming progenitors when engrafted to SCID 
mice. On the other hand, CD34
+
/CD38
+
 and CD34
−
 cell fractions did not exhibit these 
properties.
10
 Later studies from the same group provided evidence that CD34
+
/CD38
−
 
was a common immune phenotype for leukemic CSCs in multiple AML subtypes and 
also demonstrated their self
-
renewal potential.
9
 
 Additional studies have further refined and developed the cell surface 
phenotypes of AML. The Suthland group has shown that, in both in vitro and in vivo 
models, CD34
+
/CD90
−
 (Thy-1), CD34
+
/CD71
−
/HLA-DR
−
, and CD34
+
/CD117
−
 (c-kit) 
are unique cell surface marker phenotypes of AML CSCs.
39-41
 In 2000, the Jordan group 
indicated that CD34
+
/CD38
−
/CD123
+
 (interleukin-3 receptor α chain) is a specific cell 
surface phenotype for human AML stem cells.
42
 Additionally, CD123 expression has 
also been reported on CSCs in CML, myelodysplastic syndrome, and systemic 
mastocytosis,
43
 suggesting that CD123 might be a broadly applicable cell surface marker 
for the development of targeted therapies against CSCs across multiple leukemias. CD33 
is another important surface marker for characterizing AML CSCs. CD33 has long been 
known for its extensive expression on leukemic blasts,
44
 but only recently has it been 
reported as a marker for AML CSCs. Hauswirth et al. have shown that addition of 
CD33
+
 to phenotype CD34
+
/CD38
−
/CD123
+
 yields a robust marker combination for 
AML CSCs that is unique to cancerous stem cells.
45
 Additionally, Florian et al. 
demonstrated that CD34
+
/CD38
−
/CD45
+
/CD123
+
 was a general marker phenotype for 
AML CSCs and that additional markers, such as CD13
+
, CD71
−
, CD33
+
, CD117
+
, 
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CD133
+
, and HLADR
−
, were observed in variable combinations with the 
CD34
+
/CD38
−
/CD45
+
/CD123
+
 phenotype.
43
 CD34
+
/ CD38
−
/CD123
+
 CSC populations 
have also been noted for their upregulation of drug efflux pumps. Compared with bulk 
(differentiated) tumor cells, the upregulation of multidrug-resistance related protein 1, 
breast cancer resistance protein, and lung resistance protein have been observed in AML 
CSC populations.
46
 C-type lectin-like molecule-1 (CLL-1), which is a transmembrane 
protein with a heavily N-glycosylated extracellular domain, has been found to be 
exclusively expressed on AML CSCs in 92% of all studied AML cases. Isolation and 
transplantation of CD34
+
/CD38
−
/CLL
-
1
+
 cells generated AML blasts in NOD/SCID 
mice.
47
 Another important marker of AML CSCs is CD96, which belongs to the 
immunoglobulin superfamily. Recent studies have demonstrated that CD96 protein 
might be selectively overexpressed as a CD34
+
/CD38
−
/CD90
−/Lin−/CD96+ phenotype 
on AML CSCs as compared with the basal expression level of CD96 on normal HSCs.
48
 
The elevated expression of several isoforms of adhesion molecule CD44 has been 
identified in the interaction between hematopoietic progenitor cells and the surrounding 
stromal cells (i.e., CSC niche) in primary human AML samples.
49
 CD44 has been 
previously exploited in targeted drug delivery to AML CSCs 
20
 (see section “The 
chemical biology and drug targeting of cell surface markers on cancer stem cells”; Table 
1.14). The Ishikawa group has reported the identification of CD25 and CD32 in 
conjunction with CD34
+
/CD38
−
 as potential CSC markers for AML. In their study, they 
found that both CD34
+
/CD38
−
/CD25
+
 and CD34
+
/CD38
−
/CD32
+
 leukemia cells are 
enriched in quiescent, chemotherapeutic drug
-
resistant CSCs, are capable of initiating 
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AMLs in vivo, and are expressed at a very limited level in normal HSCs.
50
 Majeti et al. 
also reported CD47 as a new potential target for CSC therapy of AML. 
CD34
+
/CD38
−
/CD90
−
/Lin
−
/CD47
+
 expression was observed only in AML CSCs when 
compared with their HSC counterparts.
51
 See Table 1.1 for a listing of AML CSC 
surface markers. 
 
Table 1.1. Previously reported CSC markers for acute myelogenous leukemia (AML). 
Cancer Type Marker(s) Reference 
Acute Myelogenous Leukemia  CD34
+
/CD38
-
 
10
 
(AML) CD34
+
/CD90
-
 
39
 
 CD34
+
/CD71
-
/HLA
-
DR
-
 
40
 
 CD34
+
/CD117
-
 
41
 
 CD34
+
/CD38
-
/CD123
+
 
42,46
 
 CD34
+
/CD38
-
/CD45
+
/CD123
+
 
43
 
 CD34
+
/CD38
-
/CD123
+
/CD33
+
 
45
 
 CD34
+
/CD38
-
/CLL
-
1
+
 
47
 
 CD34
+
/CD38
-
/CD90
-
/Lin
-
/CD96
+
 
48
 
 CD44
+
 
49
 
 CD34
+
/CD38
-
/CD25
+
 
50
 
 CD34
+
/CD38
-
/CD32
+
 
50
 
 CD34
+
/CD38
-
/CD90
-
/Lin
-
/CD47
+
 
51
 
 
1.2.1.2 Acute lymphoblastic leukemia 
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and 
is characterized by clonal proliferation of lymphoblasts.
18
 ALL CSCs present the same 
CD34
+
/CD38
−
 cell surface marker phenotype as AML CSCs; however, the 
CD34
+
/CD38
−
/CD33
−
/CD19
−
 phenotype has been characterized as a more robust marker 
to define ALL CSCs.
52
 A population of ALL CSCs that are committed to lymphoid 
  10 
differentiation has been shown to express the Philadelphia chromosome 
(CD34
+
/CD38
−
/Ph
+
).
53
 The Philadelphia chromosome contains a chromosomal 
translocation between the break point cluster region (bcr) and the gene encoding c-Abl 
(abl), which encodes for the bcr-abl tyrosine kinase.
54
 The presence of the Philadelphia 
chromosome in ALL indicates an overall poor prognosis.
55
 Subsequent studies have 
shown that, in CD34
+
/CD38
−
 bone marrow cells, a predominant and aberrant 
CD34
+
/CD38
−
/ CD19
+
 cell population that is not present in healthy individuals carries 
the Philadelphia chromosome, while the CD19
−
 cell population in this compartment 
does not.
56
 These results indicate that the CD34
+
/CD38
−
/CD19
+
 phenotype marrow 
compartment in childhood ALL is another potential marker of ALL CSCs,
56
 which is 
contradictory to previous findings.
52
 However, it has been suggested that CD19
+
 might 
not be a broadly applicable AML CSC marker.
56
 ALL can be classified as T lineage (T-
ALL) or B lineage (B-ALL).
57
 Cox et al. have demonstrated that ALL cells capable of 
long
-
term proliferation and differentiation into pre-B-ALL in vitro (suspension culture 
assay) and in vivo (NOD/SCID transplant model) were derived from only CD34
+
/CD10
−
 
or CD34
+
/CD19
−
 sub
-
fractions, indicating that the target cells for transformation in pre-
B-ALL have a more immature phenotype than the bulk ALL population.
58
 The same 
group also discovered that CD34
+
/CD4
−
 or CD34
+
/CD7
−
 sub-fractions of childhood T-
ALL cells were highly proliferative and capable of NOD/SCID engraftment.
59
 More 
recently, Cox et al. reported that in childhood ALLs, the small subpopulation of 
CD133
+
/CD19
−
 cells were capable of initiating and maintaining long-term in vitro 
cultures of B-ALLs and engrafting serially into NOD/SCID recipient mice.
60
 In a recent 
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study from the Morimoto group, the stem cell characteristics of CD9
+
 cell populations in 
B-ALL were demonstrated both in vitro and in transplantation experiments, suggesting 
that CD9 is a useful positive-selection marker for the identification of CSCs in B-ALL. 
Their study also showed that, in some cases, CD9
+
 in ALL CSCs was a more reliable 
CSC marker than CD34
+
.
61
 The same group also reported the importance of CD90 (Thy-
1) and CD110 (c-Mpl) as positive-selection markers for T-ALL CSCs. In both in vitro 
and in vivo assays, their results suggested that small subpopulations of CD90
+
/CD110
+
 
cells isolated from either childhood or adult ALL specimens retained the ability to self-
renew, proliferate, and differentiate 
62
. See Table 1.2 for a listing of ALL CSC surface 
markers. 
 
Table 1.2. Previously reported CSC markers for acute lymphocytic leukemia (ALL). 
Cancer Type Marker(s) Reference 
Acute Lymphocytic Leukemia  CD34
+
/CD38
-
/CD33
-
/CD19
-
 
52
 
(ALL) CD34
+
/CD38
-
/Ph
+
 
53
 
 CD34
+
/CD38
-
/CD19
+
 
56
 
 CD34
+
/CD10
-
 
58
 
 CD34
+
/CD19
-
 
58
 
 CD34
+
/CD4
-
 
59
 
 CD34
+
/CD7
-
 
59
 
 CD133
+
/CD19
-
 
60
 
 CD9
+
 
61
 
 CD90
+
/CD110
+
 
62
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1.2.1.3 Chronic myelogenous leukemia (CML) 
CML is often characterized by the overproduction of mature myeloid cells. As 
with ALL, CML is most closely associated with the bcr-abl chromosomal translocation, 
which is present in pluripotent stem cells.
38
 CML CSCs are also characterized by the 
CD34
+
/Ph
+
 cell phenotype (Table 1) and are phenotypically similar to normal HSCs.
63
 In 
addition to its role as an AML CSC marker, CD123
+
 has also been characterized as a 
surface marker for CML CSCs (phenotype CD34
+
/CD38
−
/CD123
+
). Queries for the 
presence of other markers in CML cells bearing the CD34
+
/ CD38
−
/CD123
+
 phenotype 
revealed variable positivity for CD13, CD33, CD44, and CD117 molecules;
43
 however, 
the presence of CD117 on the surface of CML CSCs conflicts with previous reports.
41
 
See Table 1.3 for a listing of CML CSC surface markers 
 
Table 1.3. Previously reported CSC markers for chronic myelogenous leukemia (ALL). 
Cancer Type Marker(s) Reference 
Chronic Myelogenous  CD34
+
/CD38
-
/CD123
+
 
43
 
Leukemia (CML) CD34
+
/Ph
+
  
63
 
 
1.3 Cancer Stem Cells Found in Solid Tumors 
1.3.1 Breast cancer 
Breast cancer accounts for the deaths of more than 40,000 women each year in 
the United States. Although the 5-year survival rate for breast cancer patients has 
dramatically increased over the past few decades, tumor relapse and metastasis is still a 
significant problem in breast cancer therapy.
18,64
 The evasion of breast CSCs during 
therapy is a significant contributor to disease relapse.
65
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 Al-Hajj et al. were the first to identify breast CSCs from whole cell population of 
breast cancer specimens using the cell surface marker profile CD44
+
/CD24
−
/
low
/Lin
−
 
(Table 2), which was the seminal report of CSCs identified from a solid tumor.
66
 The 
marker profiles CD44
+
/CD24
−
/
low
/Lin
−
 has been correlated with high resistance to 
traditional cancer therapies,
67
 poor prognosis,
68
 and enhanced invasive properties.
69
 
Notably, lineage (Lin) markers are a standard combination of monoclonal antibodies 
including CD2, CD3, CD4, CD5, CD8, NK1.1, B220, TER-119, and Gr-1 in mice and 
CD3, CD14, CD16, CD19, CD20, and CD56 in humans.
70
 Addition of epithelial cell 
adhesion molecule (EpCAM), yielding marker combination 
CD44
+
/CD24
−
/
low
/EpCAM
high
, was later found to be a more robust surface marker 
combination for the isolation of human breast CSCs.
66
 The multiplexing of cytoplasmic 
enzyme ALDH1, membrane protein CD44, and cytokeratin has been employed to 
identify putative breast CSCs and indicate poor prognosis, which is independent of 
tumor size, nodal status, ER-, PR-, and HER2-status, and histological grade.
71
 
 Another important cell surface marker of human breast CSCs is Thy1 (CD90). In 
an MMTV-Wnt-1 breast cancer mouse model, cancer cells with the phenotype 
THY1
+
/CD24
+
 (1–4% of tumor cell population) were identified to be highly tumorigenic 
in comparison to non-THY1
+
/CD24
+
 populations and displayed properties of CSCs.
72
 
The observation of CD24
+
 phenotype in combination with Thy1 is contradictory to 
previous reports that found breast CSCs to have a CD44
+
/CD24
-
/
low
/Lin
-
 phenotype.
66
 
The expression of cell surface marker CD133 is also reported to be of significance and 
prognostic value for identifying CSCs in breast tumors, especially when combined with 
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CD44
+
.
73-75
 CD173 (H2) and CD174 (Lewis Y) are cell surface carbohydrate antigens 
that are expressed to varying extents on different human carcinomas. Co-expression of 
CD173 and CD174 with CD44 is another cell surface marker combination proposed to 
identify breast CSCs.
76
 Similar to CD173 and CD174, CD176 is also a cell surface 
carbohydrate antigen that has been reported to be co-expressed with CD44 and CD133 
in breast carcinoma.
77
 Another study has shown that in BRCA1 (breast cancer-
associated gene 1)-mutant breast cancer cell lines, a small subpopulation of cancer cells 
expressing CD24
+
/CD29
+
 (β integrin) or CD24+/CD49f+ (α6 integrin) surface markers 
exhibited enhanced proliferation and colony forming ability in vitro and increased tumor 
generating ability in vivo. In addition, purified CD24
+
/CD29
+
 cells exhibit self
-
renewal 
capability, and as low as 500 cells could reconstitute the heterogeneity of the parent 
cancer cells in vivo, which is strongly indicative of a CSC population.
78
 Shipistin et al. 
confirmed that CD201, which is also known as protein C receptor (PROCR), was 
expressed on 100% of CD44
+
 breast cancer cells and was used as a cell surface marker 
to isolate CSCs from primary invasive breast cancer tumors.
79
 In addition, high PROCR 
expression was also reported to associate with poor prognosis in clinical patients.
79
 See 
Table 1.4 for a listing of breast CSC surface markers. 
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Table 1.4. Previously reported CSC markers for breast cancer.  
Solid Tumor Type Marker(s) Reference 
Breast CD44
+
/CD24
-/low
/Lin
-
 
66,69
 
 CD44
+
/CD24
-/low
/EpCAM
high
 
66
 
 ALDH1
+
/CD44
+
/cytokeratin
+
 
71 
 CD90
+
/CD24
+
 
72
 
 CD133
+
/CD44
+
 
73-75
 
 CD173
+
/CD174
+
/CD44
+
 
76
 
 CD176
+
/CD44
+ 77 
 CD176
+
/CD133
+
 
77
 
 CD24
+
/CD29
+ 78
 
 CD24
+
/CD49f
+ 78
 
 CD44
+
/CD201 (PROCR)
+
 
79
 
 
1.3.2 Colorectal cancer 
Dalerba et al. have isolated colorectal CSCs from specimens using cell surface 
markers CD44 and EpCAM.
80
 When purified CD44
+
/EpCAM
high
 epithelial cells (Table 
2) were injected into immunodeficient mice, the engrafted tumors yielded the 
differentiated phenotype profile as well as the morphologic heterogeneity of the parent 
lesions from which the CD44
+
/EpCAM
high
 epithelial cells were isolated. Furthermore, 
the authors also reported CD166
+
 as a co-marker that could be used for validation of 
colorectal CSCs in both xenografts and primary tumors, and the 
CD44
+
/EpCAM
high
/CD166
+
 phenotype was consistent with poor prognosis.
80
 However, 
the CD44/EpCAM marker phenotypes were not the first reported colorectal CSCs. Prior 
studies had first indicated that CD133 was a potential cell surface CSC marker in 
primary human colorectal cancer,
81,82
 but more recent findings by Shmelkov et al. have 
shown that both CD133
+
 and CD133
−
 populations are tumorigenic and contain tumor
-
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initiating cells.
83
 In order to explain this discrepancy, Du et al. have suggested that, 
unlike CD44, a surface protein that is of functional importance for the survival of CSCs, 
CD133 has not been found to have any essential functions associated with the growth 
and survival of colorectal CSCs.
84
 Although CD44
+
/EpCAM
high
/ CD166
+
 is a relatively 
more reliable marker for colorectal CSCs than CD133
+
, some exceptions have also been 
documented. Lugli et al. reported that the loss of this combined marker 
(CD44
+
/EpCAM
high
/CD166
+
) was rather linked to an aggressive tumor phenotype.
85,86
 
Studies have also shown that CD49f, which has been reported as a CSC marker in breast 
cancer,
78
 is expressed on colon cancer cells, and that even higher levels of CD49f 
expression are observed with CD44
+
 cells, a known marker of colorectal CSCs.
80
 
Additionally, CD133
+
/CD24
+
 has been identified as a colorectal CSC marker.
87
 See 
Table 1.5 for a listing of colorectal CSC surface markers. 
 
Table 1.5. Previously reported CSC markers for colorectal cancer.  
Solid Tumor Type Marker(s) Reference 
Colorectal CD44
+
/EpCAM
high
 
80
 
 CD44
+
/EpCAM
high
/CD166
+
 
80
 
 CD44
+
/CD49f
+
 
80
 
 CD133
+
 
81,82
 
 CD44
+
 
88
 
 CD133
+
/CD24
+
 
87
 
 
1.3.3 Liver cancer 
The incidence of hepatocellular carcinoma (HCC) cases has risen by 3% every 
year since 1992, and the 5-year survival rate ranges from 14% to 26% depending on the 
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stage of diagnosis.
18
 In spite of the intensive research efforts devoted to the discovery of 
new HCC drugs, tumor relapse is still observed in the majority of cases.
89
 The recent 
identification of liver CSCs has yielded new targets for HCC drug discovery efforts, 
which, if successful, may help to address the problem of disease relapse. 
 The CD133
+
 phenotype was the first reported putative HCC CSC population.
90
 
In this report by Ma et al. CD133
+
 HCC cells exhibited greater colony-forming 
capacities and higher proliferation rates than CD133− HCC cells, as well as the ability to 
generate new tumors in both in vitro and in vivo models. Additionally, in CD133
+
 tumor 
cells, the expression level of stemness genes such as those involved in Wnt/β-catenin, 
Notch, and Hedgehog/SMO signaling were largely upregulated, indicating those 
CD133
+
 tumor cells were putative HCC CSCs. The CD133
+
 population was further 
characterized for other common CSC markers and CD34 and CD44 were found to be 
upregulated when compared with the CD133
−
 population.
90
 Another well-established 
cell surface marker of HCC stem cell is CD44
+
. Within the HCC CD133
+
 population, 
CD44
+
 cells were found to be more tumorigenic than CD44
−
 cells in NOD/SCID mouse 
model. Recent studies also revealed that the blocking of CD44 function by treatment 
with a CD44 specific monoclonal antibody might be a potential strategy to eradicate 
liver CSCs
91
 (see section “The chemical biology and drug targeting of cell surface 
markers on cancer stem cells”). Moreover, the cell surface carbohydrate antigen CD176 
was found to co-express with CD44 at a high rate on the surface of HCC stem cells in 
both cancer cell lines and surgical specimens of malignant tumors.
77
 Besides CD133 and 
CD44, EpCAM was identified as an early biomarker of HCC CSCs.
92,93
 The sorted 
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EpCAM
+
 subpopulation of HCC cells yielded more colonies in clonogenicity assays 
than the sorted EpCAM
−
 cells from the same cell line. Further in vivo evaluation in 
mouse models indicated that as little as 100 EpCAM
+
 HCC cells were needed to 
generate a new tumor, and EpCAM
+
 cells retained the ability to differentiate into both 
EpCAM
+
 and EpCAM
−
 cells, while EpCAM
−
 cells always sustained their phenotype 
during cell propagation.
92
 Additionally, CD133 expression was observed in both 
EpCAM
+
 and EpCAM
−
 populations, indicating that EpCAM functions as a better 
indicator of the CSC population.
93
 Recently, CD13 (alanine aminopeptidase), which is a 
membrane-bound enzyme, has been identified as a marker for semiquiescent CSCs and a 
potential therapeutic target for liver cancers. CD13
+
/CD133
+
 and CD13
+
/CD90
−
 
populations were observed to be extremely tumorigenic, requiring only 100 cells for 
tumor formation upon transplantation.
94
 In a xenograft mouse model, CD13 inhibition, 
which was achieved with either a CD13 neutralizing antibody or by the CD13 inhibitor 
Ubenimex, repressed tumor-initiating and self
-
renewing capability of the majority of 
CSCs
94
 (see section “The chemical biology and drug targeting of cell surface markers on 
cancer stem cells”). CD90 (Thy-1) has also been identified as a CSC marker in HCC cell 
lines.
95
 In comparison to CD90
−
 cells, CD90
+
 cells sorted from HCC cells lines were 
found to exhibit strong tumorigenic capacity, and the subpopulation of cells with 
CD90
+
/CD45
−
 phenotype could generate tumor nodules in an immunodeficient mouse 
model.
95
 OV6, which is a marker of hepatic progenitor (oval) cells, has been shown to 
be another CSC marker in HCC cells. OV6
+
 HCC cells are capable of generating new 
tumors in vivo and show substantial resistance to standard chemotherapeutic drugs 
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compared with OV6
−
 HCC cells. Furthermore, the inhibition of the Wnt/β-catenin 
signaling pathway, which is known to be important for the survival of CSCs,
96
 decreases 
the population of OV6
+
 cells. The OV6
+
 cell population also gained higher proliferation 
potential after β-catenin activation.97 See Table 1.6 for a listing of liver CSC surface 
markers. 
 
Table 1.6. Previously reported CSC markers for liver cancer.  
Solid Tumor Type Marker(s) Reference 
Liver CD176
+
/CD44
+
 
77
 
 CD133
+
 
90
 
 CD133
+
/CD44
+
 
91
 
 EpCAM
+
 
92,93
 
 CD13
+
/CD133
+
 
94
 
 CD13
+
/CD90
-
 
94
 
 CD90
+
/CD45
-
 
95
 
 OV6
+
 
97
 
 
1.3.4 Pancreatic cancer 
Pancreatic cancer is one of the deadliest forms of human cancers. Currently, 
there are no known methods of early detection, and the average 5-year survival rate is 
6%.
18
 The mortality rate of this disease approaches 100% because of its 
characteristically high resistance to radiation and chemotherapy, and the tendency of 
early systemic dissemination.
98
 In spite of the significant advances in cancer biology 
over the past decade, the efficacy of drugs to treat pancreatic cancer has not substantially 
improved.
99
 Targeting the pancreatic CSC population could allow development of more 
efficacious therapies to combat this lethal disease. 
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 A pancreatic CSC population was identified only recently.
99
 A small population 
(0.2–0.8%) of highly tumorigenic pancreatic cancer cells with the 
CD44
+
/CD24
+
/EpCAM
high
 phenotype (Table 2) from primary human pancreatic 
adenocarcinomas was xenografted into immunocompromised mice. In comparison with 
non
-
tumorigenic cells, the CD44
+
/CD24
+
/EpCAM
high
 pancreatic cancer cells exhibited a 
100-fold increase in tumorigenic potential, and as few as 100 such cells could 
reconstitute tumors that were indistinguishable by histology from the original ones.
99
 In 
related studies, Hermann et al. demonstrated that CD133
+
 expression on the surface of 
pancreatic cancer cells was consistent with increased tumorigenicity and high resistance 
to standard chemotherapy. In addition, they further revealed that a unique small 
population of CSCs bearing the CD133
+
/ CXCR4
+
 phenotype determined the metastatic 
potential of the tumor. Although CD133
+
/CXCR4
+
 cells and CD133
+
/ CXCR4
−
 cells 
showed similar tumorigenicity when xenografted into nude mice, only the 
CD133
+
/CXCR4
−
 cells eliminated tumor metastasis.
100
 See Table 1.7 for a listing of 
pancreatic CSC surface markers. 
 
Table 1.7. Previously reported CSC markers for pancreatic cancer.  
Solid Tumor Type Marker(s) Reference 
Pancreatic CD44
+
/CD24
+
/EpCAM
+
 
99
 
 CD133
+
 
100
 
 CD133
+
/CXCR4
+
 
100
 
 
 
 
  21 
1.3.5 Melanoma 
Approximately 70,000 new cases of human melanoma and 9,000 melanoma
-
related deaths were expected in the United States in 2011.
18
 Although melanoma is not a 
leading cause of cancer-related mortality, it is one of few cancer types associated with 
both annual increases in incidence and death rate.
101
 Human malignant melanoma cells 
are highly aggressive and drug resistant and contain cell populations with enhanced 
tumorigenicity.
102
 The discovery of putative CSCs in melanoma cell lines was first 
reported in 2005,
102
 preceding their subsequent isolation and characterization from cell 
lines and surgical specimens.
103
 Nestin (Table 2), which is an intermediate filament 
protein, was first described as a potential stem cell marker in melanoma cell lines.
104
 
Nestin expression was associated with aggressive behavior of the malignant tumors and 
was found to be upregulated during the development of invasive melanoma from banal 
nevi (a benign chronic lesion of the skin).
104
 Co-expression of nestin with CD133 has 
been described in context with stem cell populations in circulating melanoma cells, 
which are closely related to their metastatic potentials.
105
 Monzani et al. first utilized 
CD133 as a cell surface marker to separate melanoma stem cells. Their data showed that 
in contrast to CD133
−
 cells, CD133
+
 melanoma cells were highly tumorigenic and able 
to generate a Mart-1 (a typical melocytic marker) positive tumor when implanted into 
NOD/SCID mice. In the same study, they also revealed that melanoma cells expressing 
both CD133 and ABCG2 (ATP-binding cassette sub-family G member 2) were able to 
self-renew and differentiate into astrocytes and mesenchymal lineages under specific 
conditions, demonstrating the utility of ABCG2 as a CSC marker.
103
 Schatton et al. 
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identified a small subpopulation of melanoma cells that were enriched for human 
malignant melanoma-initiating cells, which were defined by the expression of P-
glycoprotein ABCB5, a well-known chemoresistance mediator. ABCB5
+
 melanoma 
cells were found to be highly aggressive, possess greater tumorigenic capacity than 
ABCB5
−
 cells, and could re-establish clinical tumor heterogeneity. ABCB5 has also 
been studied as a target of anticancer therapy
106,107
 (see section “The chemical biology 
and drug targeting of cell surface markers on cancer stem cells). See Table 1.8 for a 
listing of melanoma CSC surface markers. 
 
Table 1.8. Previously reported CSC markers for skin cancer.  
Solid Tumor Type Marker(s) Reference 
Skin CD133
+
 
103
 
 CD133
+
/ABCG
-
2
+ 103
 
 Nestin
+
/CD133
+ 105
 
 ABCB5
+
 
107
 
 
1.3.6 Brain cancer  
Malignant brain tumors are among the deadliest human cancers. Glioblastoma 
(GBM) multiforme is the most common primary brain tumor in adults with 12,000 
deaths in the United States annually.
108
 In children, glioblastoma multiforme occurs less 
frequently, accounting for 7–9% of all intracranial tumors, yet the median survival after 
diagnosis is 50 weeks.
109
 Currently, there is a scarcity of effective treatments for brain 
cancers, which is attributable to the sensitive environment of the disease and the 
inability of many drugs to permeabilize the blood–brain barrier. Unfortunately, most 
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drugs that can access brain malignancies are inefficient at eradicating the tumor cells and 
frequently leave behind a side population of radio- and chemoresistant cells. The 
existence of this side population provides a mechanism for disease relapse,
33
 and recent 
studies strongly suggest that brain tumors have an established CSC hierarchy.
110,111
 Drug 
targeting of brain CSCs may yield better therapy outcomes. 
 In 2003, Singh et al. first identified CD133 as a CSC marker (Table 2) in 
glioblastomas and medulloblastomas.
112
 Studies of human medulloblastoma specimens 
from children have also revealed a CD133
+
 subpopulation of cells that is positive for 
nestin.
113
 Sorted CD133
+
 populations of childhood medulloblastoma specimens have 
demonstrated the stem cell characteristics of self-renewal and differentiation, and 
subjection of these cells to differentiation conditions resulted in the loss of the CD133
+
 
marker.
112
 The tumorigenicity of CD133
+
 human donor medulloblastoma and 
glioblastoma cancer cells were evaluated in NOD/SCID mice, and as few as 100 cells 
were required for the development of new tumors of the same phenotype.
113
 
 Another glioblastoma CSC marker that has been identified is integrin A2B5, a 
polysialo ganglioside. Tchoghandjian et al. used A2B5 to characterize CSC populations 
in glioblastoma samples using magnetic micro-beads and FACS. In addition, the authors 
sorted the cells for a secondary known CSC marker, CD133. A2B5
+
 populations 
expressed characteristic features of CSCs regardless of CD133 expression, and both 
A2B5
+
/CD133
+
 and A2B5
+
/CD133
−
 populations were highly tumorigenic, requiring 
only 1,000 cells for development of a new tumor of the same phenotype. However, only 
the A2B5
+
/CD133
−
 population of cells was found to be invasive within the brain.
114
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Studies by Ogden et al. have suggested that only the A2B5
+
 phenotype is characteristic 
of glioblastoma CSCs, and CD133 positivity is not indicative of a CSC population.
115
 In 
support of the evidence that CD133
+
 cells are putative CSCs, studies by Wang et al. 
found that CD133
+
 glioblastomas were aggressive tumors and were typified by the onset 
of angiogenesis, shorter survival times, and metastatic potential. However, the CD133
−
 
populations were also shown to be capable of differentiating into CD133
+
 cells, which 
suggests that CD133
−
 are stem cell-like.
116
 Although characterization of universal 
diagnostic markers for CSCs is the ultimate goal for the development of targeted 
therapies, these contradictory results with CD133 clearly illustrate that patients can 
express different surface markers for the same disease and/or that multiple CSC 
populations can be present in glioblastoma specimens. 
 L1CAM, a transmembrane adhesion protein found in CD133
+
 glioma cell 
populations, was identified as a brain CSC marker in 2008.
117
 D456MG pediatric 
glioblastoma xenografts and primary human samples were utilized to study the role of 
L1CAM.
118
 Neurosphere formation, a cellular morphology consistent with a stem cell-
like state, was quantified as a measure of the self
-
renewal properties of the CSC 
population. Targeting L1CAM with shRNA decreased the ability of the CD133
+
 cells to 
form neurospheres, indicating that the L1CAM
+
/CD133
+
 population was the in vitro 
CSC population. In vivo studies conducted in nude mice also showed that knockdown of 
L1CAM with shRNA resulted in a reduction in tumor size and increased survival.
117
  
 Stage
-
specific embryonic antigen-1 (SSEA-1), or CD15, has also been identified 
as a potential marker of GBM CSCs.
119
 Utilizing primary human samples, SSEA-1
+
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cells were isolated and characterized for self-renewal, differentiation, and 
tumorigenicity. The presence of CD133
+
 was also investigated in the SSEA-1
+
 
populations in early studies; however, SSEA-1
+
/CD133
+
 and SSEA-1
+
/CD133
-
 were 
both shown to have CSC characteristics. Sorting of primary human GBM specimens for 
only SSEA-1 expression and xenograftment of isolated cells into NOD/SCID mice 
revealed that SSEA-1
+
 cells exhibited at least 100-fold greater tumorigenic potential 
than SSEA-1
−
 GBM cells. Therefore, SSEA-1
+
 can be used to identify CSC populations 
in GBM.
119
 SSEA-1 has also been identified as a medulloblastoma CSC marker.
120
 See 
Table 1.9 for a listing of brain CSC surface markers. 
 
Table 1.9. Previously reported CSC markers for brain cancer.  
Solid Tumor Type Marker(s) Reference 
Brain CD133
+
 
112
 
 CD133
+
/Nestin
+
 
113
 
 CD133
+
/A2B5
+ 
and CD133
-
/A2B5
+
 
114
 
 A2B5
+
 
115
 
 CD133
+
/L1CAM
+
 
117
 
 SSEA
-
1
+
 
119
 
 
1.3.7 Lung cancer 
Lung cancer is the most common, yet preventable, cancer related death 
worldwide, resulting in more mortalities than colon, breast, and prostate cancers 
combined. The 5-year survival rate for small cell lung carcinoma is 6% while nonsmall 
cell carcinoma is 17%.
18
 Current lung cancer therapies are usually transient and fail to 
completely eradiate the tumor, causing resistance. One potential hypothesis for drug 
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resistance to chemotherapy is the presence of drug refractory lung CSC populations in 
the tumor masses.
121
 Eramo et al. identified CD133
+
 CSC subpopulations (Table 2) in 
small cell and non-small cell lung cancer from primary human donors. CD133 
expression was observed on the surface of 0.32–22% of lung cancer cells by flow 
cytometry analyses, which varied depending on different disease stages of the sample. In 
vivo analysis showed that tumor formation required only 1,000 cells to be implanted into 
SCID mice, while differentiated cell populations injected at 50,000 cells per animal 
failed to produce tumors.
122
 CD176 has also been identified as a potential marker for 
lung CSC populations and has been observed in combination with CD133 and CD44 cell 
surface markers. CD176
+
/CD133
+
 and CD176
+
/CD44
+
 phenotypes were observed after 
sorting cells for CD176 expression, and CD176
+
 cell populations were found to exhibit 
features of CSCs, such as tumorigenicity. These results imply that CD176
+
 may be used 
as a potential lung CSC marker.
77
 See Table 1.10 for a listing of lung CSC surface 
markers. 
 
Table 1.10. Previously reported CSC markers for lung cancer.  
Solid Tumor Type Marker(s) Reference 
Lung CD176
+
/CD44
+
 
77
 
 CD176
+
/CD133
+
 
77
 
 CD133
+
 
122
 
 
1.3.8 Bladder cancer 
Bladder transitional cell carcinoma (BTCC) is the second most prevalent cancer 
of the urinary tract.
123
 Five-year survival rates for BTCC vary by stage of development, 
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ranging from 6% to 97%.
18
 Traditional therapy consists of surgery, radiation, and 
chemotherapy,
124
 but if disease becomes invasive, then treatment outcomes are typically 
poor due to metastasis.
125
 The development of diagnostic markers and new therapies for 
BTCC is currently needed. 
 Yang and Chang have identified a subpopulation of BTCC samples from primary 
human donors that display a CD44
+
/EMA
−
 (epithelial membrane antigen) phenotype 
(specifically the isoform CD44v6; Table 2). CD44
+
/EMA
−
 populations were shown to 
overexpress Bmi-1 and EZH2, which are proteins that play a role in self-renewal of 
normal bladder stem cells. CD44
+
/EMA
−
 cells also were able to form colonies and 
proliferate in vitro, which are characteristic features of CSCs.
126
 
 Chan et al. have also postulated that BTCC CSCs can be characterized by the 
cell surface phenotype Lin
−
/CD44
+
/cytokeratin (CK)5
+
/CK20
−
. Tumors from primary 
human donors were sorted for CD44
+
 and CD44
−
 cells and then transplanted into 
immunocompromised mice (RAG2
−/γc−). The CD44+ cells were found to be more 
tumorigenic, requiring only 100–1,000 cells to form tumors, while the CD44− population 
required 200,000–500,000 cells to elicit tumors in mice. Immunofluorescence analysis 
of CD44
+
 xenografts showed co
-
expression of CK5 and lack of expression of CK20 
(phenotype Lin
−
/CD44
+
/CK5
+
/ CK20
−
), and this marker phenotype was deemed to be 
the BTCC CSC population. The authors also queried for other common CSC cell surface 
markers and discovered that CD47 is highly expressed on CD44
+
 cells. CD47 inhibits 
phagocytosis by macrophages, allowing for pathogenesis of the bladder cancer.
125
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 Hoechst 33342 dye is a widely used indicator of side populations with potential 
CSC characteristics.
127
 ATPbinding cassette (ABC) and multidrug resistance efflux 
pumps are responsible for the elimination of Hoechst 33342 dye, as well as cytotoxic 
drugs, from cells. This process is detectable by FACS and allows for the identification 
and isolation of subpopulations of cells displaying these characteristics that are common 
of CSCs.
127,128
 ABC-G2 transporters were detected in the BTCC cell line T24. ABC-G2
+
 
and ABC-G2
−
 cells were cultured in vitro, and their growth characteristics were 
evaluated. ABC-G2
+
 cells demonstrated consistent proliferation, whereas the ABC-G2
−
 
did not. Side populations of ABC-G2
+
 also were able to differentiate into ABC-G2
−
 
cells, which further supports the hypothesis that ABC-G2
+
 is a marker of BTCC 
CSCs.
127
 See Table 1.11 for a listing of bladder CSC surface markers. 
 
Table 1.11. Previously reported CSC markers for bladder cancer.  
Solid Tumor Type Marker(s) Reference 
Bladder Lin
-
/CD44
+
/CK5
+
/CK20
-
 
125
 
 CD47
+
/CD44
+
 
125
 
 CD44v6
+
/EMA
-
 
126
 
 ABC
-
G2
+
 
127
 
 
1.3.9 Prostate cancer 
Prostate cancer is the most commonly diagnosed malignancy and second leading 
cause of death in men in the United States.
18
 More than 80% of men will develop 
prostate cancer in their lifetime, and most diseases will not be diagnosed.
129
 Prostate 
cancer is routinely treated by hormone ablation therapy, but this therapy regimen fails 
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when the disease progresses to a hormone
-
refractory state.
130
 Currently, cytotoxic small 
molecules are the only therapeutic regimen able to improve outcomes for patients with 
hormone-refractory prostate cancers.
131
 Identification of CSC surface markers could 
provide a foundation for the development of next
-
generation drugs that target prostate 
CSCs.
130
 
 The first CSC surface marker identified for prostate cancer was CD44 (Table 2). 
In 1997, Liu et al. reported their observation that CD44
+
 prostate cancer cells were 
negative for prostate-specific antigen (PSA) and prostate acid phosphatase secretion, 
which are proteins that are produced during cancer cell differentiation. On the other 
hand, when CD44
+
 prostate cancer cells were co-cultured with stromal cells, the 
secretion of PSA was detected, indicating that the interaction between stromal cells and 
CD44
+ 
prostate cancer cells stimulated the differentiation ability of the latter, since PSA 
production was not detected when either stromal cells or CD44
+ 
prostate cancer cells 
when cultured alone.
88
 Collins et al. demonstrated that prostate CSCs could be identified 
from human specimens with a CD44
+/α2β1high/ CD133+ phenotype, and this population 
comprised 0.1– 0.3% of the total amount of cells in the tumor. In a colony-forming 
assay, the CD44
+/α2β1high/CD133+ population yielded 3.7-fold greater number of 
colonies compared with the total cell population and more than 30-fold greater number 
of colonies compared with CD44
+/α2β1hi/CD133− or CD44+/α2β1low cells, which 
suggests the CD44
+
/α2β1high/CD133+ phenotype has the ability to self-renew.28 
Patrawala et al. performed in vivo studies in NOD/SCID mice utilizing prostate cancer 
cell lines that were enriched for the CD44
+/α2β1high combination phenotype.132,133 They 
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found that the CD44
+/α2β1high population had greater tumorigenicity than other 
populations isolated (CD44
+/α2β1low, CD44−/α2β1high, CD44−/α2β1low), further 
supporting the evidence that the CD44
+/α2β1high phenotype is the CSC population.133 
 Mulholland et al. later confirmed that the Lin
−
/Sca-1
+
/CD49f
high
 subpopulation of 
prostate cancer cells were CSCs in a murine prostate PTEN
−
 model (PTEN is a tumor 
suppressor gene in the protein kinase B pathway).
130
 The loss of PTEN activity is 
strongly associated with the initiation and metastasis of prostate cancer.
134
 Tissue 
samples were taken from murine PTEN mutant prostate tumor grafts on SCID mice after 
6–8 weeks, digested into single-cell suspensions, and sorted by FACS. Through a 
systematic study of various potential surface markers, Sca-1 and CD49f were identified 
as surface markers of prostate CSCs. Sorted cells (Lin
−
/Sca
-
1
+
/CD49f
high
 and Lin
−
/Sca-
1
+
/ CD49f
low
) were then injected into SCID mice and only Lin
−
/Sca-1
+
/CD49f
high
 cells 
induced tumor growth.
130
 See Table 1.12 for a listing of prostate CSC surface markers. 
 
Table 1.12. Previously reported CSC markers for prostate cancer.  
Solid Tumor Type Marker(s) Reference 
Prostate CD44
+/α2β1
high
/CD133
+
 
28
 
 Lin
-
/Sca
-
1
+
/CD49f
high
 
130
 
 CD44
+
/α2β1
high
 
133
 
 
1.3.10 Ovarian cancer 
The most lethal disease of the female reproductive tract is ovarian cancer.
135
 
High mortality rates occur due to the difficulty in diagnosing early stage ovarian cancer 
as well as the high prevalence of drug-refractory relapse after initial treatment, which is 
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likely a result of CSC subpopulations that survive therapy.
136
 Ovarian cancer 5-year 
survival rates vary depending on the stage of development of the tumor. Early stage 
diagnosis, when the disease has yet to metastasize, has a 5-year survival rate of 73%, 
while late-stage ovarian cancer diagnosis results in a 28% survival rate.
18
 
 Zhang et al. first identified CD44 as a potential ovarian CSC surface marker in 
2008. Analysis of human ovarian specimens revealed a small population (0.14–0.2%) of 
CD44
+
/CD117
+
 cells (Table 2) that were highly tumorigenic and demonstrated self-
renewal by spheroid formation. Tumorigenicity was measured by engraftment of 
CD44
+
/CD117
+
 and CD44
−
/CD117
−
 subpopulations into nude mice. The 
CD44
+
/CD117
+
 subpopulation was able to repopulate the tumor following injection of 
only 100 cells, whereas the isolated CD44
−
/CD117
−
 phenotype required 500,000 cells 
for tumor development after 3 months.
135
 
 Ferrandina et al. identified CD133
+
 subpopulations as ovarian CSCs in primary 
human samples. The CD133
+
 subpopulation was 4.7-fold more active in a colony-
forming assay, which demonstrated replicative capacity.
137
 Work by Curley et al. 
verified the presence of a CD133
+
 subpopulation with tumor-initiating properties and 
found that 0.2– 12.5% of the tumors expressed this phenotype.138 
 CD24
+
 has also been characterized as a potential surface marker of human 
ovarian CSCs. Two weeks after the plating of isolated CD24
+
 ovarian cancer cells, 
analysis of the cell population revealed both CD24
+
 and CD24
−
 phenotypes, which 
suggests that CD24
+
 cells are CSCs due to their ability to self-renew and differentiate. 
Conversely, the same experiment performed with CD24
−
 cells failed to yield CD24
+
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cells after the same amount of time in culture. Additional in vivo studies demonstrated 
that only 5,000 CD24
+
 cells were needed for tumor formation after injection into nude 
mice, whereas CD24
−
 cells injected at the same concentration were unable to generate 
tumors.
139
 Therefore, CD24
+
 cells are more tumorigenic than CD24
-
 cells. 
 To add to the growing number of ovarian CSC markers, Wei et al. isolated a 
triple surface marker phenotype, CD44
+
/CD24
+
/EpCAM
+
, which best characterized the 
most proliferative cell subpopulation when compared with all other marker 
combinations. Cells lines OVCAR-5, SKOV-3, and IGROV-1, as well as primary 
human donor samples were used for experiments. Colony-formation assays were 
performed on CD44
+
/CD24
+
/EpCAM
+
 sorted cells to measure proliferation rates and to 
characterize self
-
renewal properties. In vivo studies were performed comparing 
CD44
+
/CD24
+
/EpCAM
+
 and CD44
−
/CD24
−
/EpCAM
−
 phenotypes by injection into 
NOD/SCID mice. These studies demonstrated that as few as 100 
CD44
+
/CD24
+
/EpCAM
+
 cells injected in NOD/SCID mice were capable of tumor 
formation, and CD44
+
/CD24
+
/EpCAM
+
 cells grew tumors faster and more aggressively 
than the CD44
−
/CD24
−
/EpCAM
−
 population.
140
 Consequently, the 
CD44
+
/CD24
+
/EpCAM
+
 phenotype was deemed to be more tumorigenic and likely a 
CSC population. See Table 1.13 for a listing of ovarian CSC surface markers. 
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Table 1.13. Previously reported CSC markers for ovarian cancer. 
Solid Tumor Type Marker(s) Reference 
Ovarian CD44
+
/CD117
+
 
135
 
 CD133
+
 
137,138
 
 CD24
+
 
139
 
 CD44
+
/CD24
+
/EpCAM
+
 
140
 
 
1.4 The chemical biology and drug targeting of cell surface markers on cancer stem 
cells 
The repertoires of cell surface macromolecules found on CSCs are widely used 
as markers for characterizing CSC populations (described previously). In addition to 
these diagnostic applications, the unique molecules that are presented on the surfaces of 
CSCs are valuable targets for drug delivery. However, many of the surface markers that 
are presented on CSCs are known to also be expressed at varying levels on the surfaces 
of normal, non-cancerous cells. Some of the reported CSC surface markers, in addition, 
have not been rigorously queried for expression across panels of non-cancerous tissue. 
Therefore, cell surface markers that are selected for targeted drug delivery applications 
must be evaluated for cancer cell selectivity during development studies to probe for off-
target effects.
8
 In the following section we review, where known, several of the 
established chemical and structural features that are characteristic of the most common 
CSC surface molecules, as well as previous efforts to deliver therapeutic agents to CSCs 
by targeting their unique cell surface markers. We recognize that an equally exciting 
area of intense investigation involves the identification of small molecules that possess 
CSC inhibitory properties, such as the recent reports of the anti-CSC activities of the 
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natural products parthenolide and salinomycin.
19,141
 However, we have focused here on 
those therapeutic molecules that target CSC surface markers as part of their mechanism 
of inhibition.  
 
1.4.1 CD133  
 CD133 is a five-transmembrane protein consisting of 865 amino acid residues. It 
consists of two extracellular glycosylated loops and two cytoplasmic loops, bringing the 
final molecular weight of CD133 to 120 kDa.
142
 Under bioenergetic stresses, such as 
hypoxic conditions, CD133 expression is upregulated significantly.
143
 No ligands or 
signaling mechanisms have been defined for CD133. Although the biological functions 
of CD133 have not been fully elucidated, the localization of CD133 to protrusions in the 
plasma membrane suggests a possible role in membrane organization.
143
 The rationale 
for this hypothesis is the observation that CD133 is commonly located on cell membrane 
protrusions, such as microvilli-like structures on epithelial cells, which are important for 
increasing the surface area and the reabsorption characteristics of those cells.
144,145
 In 
addition to its presence on CSCs from multiple diseases (vide supra), CD133 is 
commonly found as a marker of somatic stem cells, ranging from hematopoietic, neural, 
prostate, kidney, liver, and pancreas.
146
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Table 1.14: Targeting of CSC populations by antibodies and small molecules. 
 
Antibody/Agents Description Cancer Indication Reference 
Clone7 
 
Monoclonal antibody against 
CD133 
Brain 
 
147
 
 
CD133 targeted 
carbon nanotubes 
 
 
Single walled carbon nanotubes 
functionalized with anti
-
CD133 
monoclonal antibodies 
 
Brain 
 
 
 
36
 
 
 
 
CD133 targeted lipid 
nanocapsules 
 
 
Lipid nanocapsules functionalized 
with anti
-
CD133 monoclonal 
antibodies 
 
Colorectal 
 
 
 
148
 
 
 
 
Catumaxomab 
 
 
Monoclonal trifunctional antibody 
against EpCAM, CD3 and APCs 
 
Malignant ascites, ovarian and 
gastric 
 
149
 
 
 
MT110 
 
 
Monoclonal single chain 
bispecific antibody against 
EpCAM and CD3 
Colorectal, lung, gastric 
 
 
150
 
 
 
Edrecolomab 
 
Monoclonal antibody against 
EpCAM 
Colorectal 
 
151
 
 
Adecatumumab  
(MT201) 
Monoclonal antibody against 
EpCAM 
Breast, colorectal, prostate 
 
152
 
 
H90 
 
 
Monoclonal antibody against 
CD44 
 
Acute myelogenous leukemia 
 
 
20
 
 
 
P245 
 
Monoclonal antibody against 
CD44 
Breast 
 
153
 
 
Gemtuzumab 
ozogamicin (GO) 
 
Small molecule
-
anti
-
CD33 
antibody conjugate 
 
Acute myelogenous leukemia 
 
 
154,155
 
 
 
3C2
-
1D12 
 
Monoclonal antibody against 
ABCB5 
Melanoma 
 
156
 
 
Ubenimex 
 
Dipeptide small molecule inhibitor 
of CD13 
Liver 
 
94
 
 
7G3 
 
Monoclonal antibody against 
CD123 
Acute myelogenous leukemia 
 
157
 
 
Clone B6H12.2 
 
Monoclonal antibody against 
CD47 
Acute myelogenous leukemia 
 
51
 
 
 
 CD133 is one of the most prominent CSC surface markers. Although a multitude 
of monoclonal antibodies against CD133 have been previously described, most 
commercially available CD133 antibodies have limited applicability because they only 
recognize glycosylated CD133
+
 epitopes.
158
 Consequently, the majority of CD133 
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antibodies fail to identify the entire CD133
+
 population. Nonetheless, a repertoire of 
CD133-recognizing antibodies is available for various uses. 
 Clone7 is an anti-human CD133
+
 monoclonal antibody that recognizes 
glycosylated, as well as non-glycosylated, epitopes of CD133. Clone7 allows for 
multiple experiments with CD133 to be performed regardless of post-translational 
glycosylation status. Clone7 can be utilized in Western blotting, immunofluorescence, 
flow cytometry, and immunohistochemistry applications.
147
 
 Single-walled carbon nanotubes functionalized with anti-CD133 antibodies to 
actively target CD133
+
 have been developed by Wang et al. Selective uptake of the 
nanotubes was observed only in the CD133
+
 population, and phototherapy eradication of 
the CD133
+
 cells bearing the nanotubes was achieved by absorption of 808-nm near IR 
light.
159
 This study has yielded a potential photothermal approach to selectively target 
CD133
+
 glioblastoma cells. 
 Lipid nanocapsules functionalized with anti-CD133 antibodies have been shown 
to target CD133
+
 CSCs, in recent work by Bourseau-Guilmain et al. Selective uptake by 
the CD133
+
 population was observed by fluorescence of Nile red, which was loaded into 
the lipid nanocapsules. Loading of hydrophobic drugs into the lipophilic cores of the 
nanocapsules are now being tested for the direct therapeutic targeting of CD133
+
 tumors 
with the goal of diminished side effects.
148
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1.4.2 Epithelial cell adhesion molecules  
 EpCAM is a single transmembrane domain glycoprotein that plays a major role 
in cell-to-cell adhesion, both constructive and disruptive.
160
 EpCAM is specifically 
expressed on epithelial cancers such as breast, colorectal, pancreatic, liver and ovarian 
tumors and can interfere with cell-to-cell adhesion in various ways. One interference 
method is the disruption of the bonding of α-cadherin and F-actin, which translates into 
a loss of E-cadherin-mediated cell-to-cell adhesion.
161
 Alternatively, EpCAM was 
originally observed to prevent cell scattering due to cellular adhesion characteristics.
162
 
Because of this dual role in adhesion of cells, EpCAM expression is both tumor-
promoting as well as tumorsuppressive. The role EpCAM takes within a tumor is 
dependent on the tumor type.
160
 
 Catumaxomab (Removab
®
, developed by Fresenium Biotech GmbH and Trion 
Phama) is a rat–mouse hybrid monoclonal and tri-functional antibody against EpCAM, 
CD3 antigen in T cells, and antigen-presenting cells (APC; such as microphages, natural 
killer cells, and dendritic cells).
163,164
 Its capability of binding three different types of 
cells comes from its unique structure: it is a heterozygous antibody with one chain of 
mouse anti-EpCAM antibody and one chain of rat anti-CD3 antibody. The heavy-chain 
Fc region of both chains can bind to the Fc receptors on APCs. Catumaxomab is more 
than 1,000-fold more potent than a monospecific anti-EpCAM antibody in killing cancer 
cells.
163,164
 Catumaxomab does not require the utilization of any additional reagent(s) to 
stimulate the immune response. The different specificities of the antigen binding sites of 
the two antibody chains enable simultaneous recognition of both tumor cells (especially 
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CSCs) and T cells, and the functionalized heavy chain Fc domain is able to recruit and 
stimulate APC, resulting in the initiation of complex immune reactions. In a pivotal 
phase II/III clinical study, Catumaxomab treatment lead to activation of peritoneal T 
cells and a completion elimination of CD133
+
/EpCAM
+
 cells from the peritoneal fluid 
of malignant ascites patients.
165,166
 Catumaxomab was approved in the European Union 
in 2009 and is undergoing phase III clinical trials in the United States for the treatment 
of malignant ascites, ovarian cancer, and gastric cancer.
149
 In addition to Catumaxomab, 
there are other bi-functional or trifunctional EpCAM-targeting antibodies undergoing 
preclinical studies or clinical trials. 
 MT110 (developed by Micromet GmbH) belongs to a class of single-chain 
antibodies called bispecific T cell engager or BiTE. MT110 was constructed by coupling 
the antigen binding domains of α-CD3 and α-EpCAM monoclonal antibodies, yielding a 
hybrid antibody with specificity for both EpCAM and CD3.
167
 A BiTE antibody enables 
the generation of a cytolytic synapse between a cytotoxic T cell and a target cell that 
binds to the BiTE antibody.
168
 In the case of MT110, the target cell is a tumor cell that 
expresses the EpCAM cell surface marker. The formation of the cytolytic synapse 
induces T cells for redirected lysis of the EpCAM
+
 target cell at pico- to femtomolar 
concentrations.
167
 MT110 has been shown to have high antitumor activity in various 
animal models
167,169
 and is capable of completely eliminating colorectal CSCs in cell 
culture and in animal models.
170
 MT110 is currently in phase I clinical trials in the 
United States for lung and gastrointestinal cancers.
150
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 Edrecolomab (Mab17-1A, Panorex®, developed by Cancer and Leukemia Group 
B) was one of the first monoclonal antibodies administered to humans for cancer 
therapy. Edrecolomab is a low-affinity murine IgG2a monoclonal antibody that targets 
the cell-surface glycoprotein EpCAM. Because of the extensive basal level expression of 
EpCAM molecules on normal epithelial cells,
171
 the toxicity of EpCAM-targeting 
antibodies was viewed as a potential obstacle for the development of this class of 
therapies.
172
 Since the expression level of EpCAM on the surface of CSCs is much 
higher than it is on the surface of normal epithelial cells, the designed low-affinity 
edrecolomab decreases the possibility of off
-
target effects while maintaining efficacy for 
targeting CSCs, which makes edrecolomab a well-tolerated drug with a relatively wide 
therapeutic window.
172
 Edrecolomab, which is thought to eliminate tumor cells by 
antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement-dependent 
cytotoxicity (CDC),
152,173
 underwent phase II–III clinical trials in the United States as a 
potential postoperative adjuvant treatment of stage II colon cancer. However, the clinical 
trial was terminated in 2005 because of lack of improvement of overall or disease-free 
survival.
151
 
 Adecatumumab (MT201, developed by Micromet GmbH) is a fully humanized, 
recombinant IgG1 monoclonal antibody that specifically binds to EpCAM with low 
affinity. It was designed to retain the safety profile, yet improve the antitumor potency 
of edrecolomab. MT201 exhibited EpCAM-specific CDC with potency similar to that of 
edrecolomab, but the efficacy of ADCC induction of MT201 was two-fold greater than 
that of edrecolomab.
152
 It also has been reported that the combination of adecatumumab 
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and docetaxel is safe and efficacious in heavily pretreated advanced-stage breast cancer 
patients.
174
 MT201 is now in phase II clinical trials in the United States for the treatment 
of prostate, colorectal, and metastatic breast cancers.
152
 
 
1.4.3 CD44  
 The lymphocyte adhesion receptor CD44, first described in 1983,
175
 is a 
transmembrane glycoprotein that binds hyaluronate (HA).
176
 CD44 was first cloned in 
1989,
177
 and the binding domain was crystallized in 2004 (PDB 1POZ).
178
 CD44 is 
involved in many important cellular processes, including cell growth, survival, 
differentiation, and apoptosis.
179-181
 CD44 plays a crucial role in cancer migration and 
matrix adhesion in response to the cellular microenvironment, and high CD44 levels are 
associated with increasing cellular aggregation and tumor metastatic potential.
176
 The 
importance of CD44 in cancer cells, especially in CSCs, is closely related to its unique 
structure and function. The extracellular domain of CD44, which is a globular structure, 
contains two domains: a link domain and a HA binding domain.
176,182
 Binding sites for 
microenvironment proteins, such as laminin, collagen, and fibronectin,
183,184
 receptors 
such as E- and L-selectin,
185
 and other glycosaminoglycans have also been 
characterized.
186
 The transmembrane region of CD44 contains a glycolipid-enriched 
microdomain (GEM), which is responsible for the oligomerization of CD44s.
187
 The 
crosslinking and GEM association of CD44s, which is often induced by the binding of 
HA or other ligands, leads to a conformational change of the molecule and is important 
in CD44-mediated signal transduction.
188
 The main function of the cytoplasmic domain 
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of CD44 is to recognize its partner molecules ankyrin, ezrin, radixin, and moesin 
(ERM). ERM proteins are cytoskeleton proteins that regulate cell migration, cell shape, 
and protein resorting in the plasma membrane.
189
 The unique structure of CD44 
molecules indicates that they are functionally important to CSCs. CD44 regulates cancer 
cell adhesion and homing,
26
 cell extravasation and migration,
190
 the crosstalk between 
stem cells and their niche,
191
 epithelial mesenchymal transition,
192
 and the repression of 
cell apoptosis.
193
 Each of these functions contributes to the observation that CD44 is one 
of the most prevalent surface markers in CSCs.
194
 CD44 is a cell surface marker 
extensively expressed on the surface of a large range of CSCs including AML, bladder, 
breast, colorectal, liver, ovarian, pancreatic, and prostate cancers (Tables 1 and 2). 
 H90 is an anti-CD44 monoclonal antibody that was first reported by John Dick 
and colleagues in 2006 as a therapeutic approach to treat AML.
20
 Currently, the majority 
of leukemia chemotherapeutics are antiproliferative drugs that target rapidly cycling 
leukemic cells. However, disease relapse is observed in more than 70% of adult patients, 
indicating that quiescent AML CSCs have not been effectively removed.
195
 AML CSCs 
are more difficult to target than highly proliferative and differentiated leukemic cells due 
to their quiescent nature. However, the survival and self-renewal of AML CSCs requires 
attachment to extracellular niche proteins.
196
 Thus, targeting the interaction between 
niche proteins and AML CSCs, which is mediated by the cell surface marker CD44, may 
provide a mechanism to eradicate AML CSCs.
197
 In vivo administration of H90 to 
NOD/SCID mice transplanted with human AML showed a significant decrease in 
leukemia repopulation.
20
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 P245 is another CD44-specific monoclonal antibody with a design and targeting 
rationale similar to H90. Administration of P245 to human breast cancer xenografts 
markedly decreased the growth of tumor cells and effectively prevented tumor relapse 
after chemotherapy-induced remission. P245 is now under preclinical study for the 
treatment of breast cancer.
153
 Both of the above CD44-specific antibodies also have the 
effect of inducing differentiation in CSCs.
26
 
  
1.4.4 CD33  
 CD33 is a myeloid cell surface antigen that is expressed on leukemic blasts from 
85% - 90% of AML patients,
44
 and the combination phenotype 
CD34
+
/CD38
−
/CD123
+
/CD33
+
 is uniquely expressed on the surface of AML CSCs.
45
 
CD33 is a single transmembrane protein that is activated by phosphorylation.
198
 CD33 
functions as a putative adhesion molecule of monocytic and myeloid lineage cells and 
modulates sialic acid-dependent binding and cell differentiation.
44
 In immune responses, 
CD33 acts as an inhibitory receptor of ligand binding induced tyrosine phosphorylation 
by recruiting cellular phosphatases to its SH2 domain and blocking signal transduction 
through hydrolysis of the phosphates of signaling molecules.
199,200
 CD33 also induces 
apoptosis in acute myeloid leukemia through mechanisms that are not fully 
characterized.
201
 
 Gemtuzumab ozogamicin (Mylotarg
®
, developed by Wyeth and Pfizer) is a 
small-molecule–anti-CD33 monoclonal antibody conjugate. The small-molecule 
component of this drug is N-acetyl γ-calicheamicin dimethyl hydrazide, a stable 
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enediyne antitumor antibiotic that was identified from a screen of potent DNA 
alkylators.
202
 The antibody component is a humanized IgG4 anti-CD33 antibody 
(hP67.6) that is conjugated to calicheamicin by an acidlabile hydrazone linker. Studies 
have shown that the antibody–drug conjugate exhibits good potency, as well as 
selectivity, which is attributed to its property of only releasing the DNA alkylator in the 
acidic environment of cellular lysosomes (i.e., it is stable in blood).
154,155
 The antibody 
component of gemtuzumab ozogamicin (GO) is largely non-toxic and functions to 
facilitate the uptake of calicheamicin into CD33
+
 AML cells. Once released, 
calicheamicin undergoes rearrangement to form a diradical metabolite that is capable of 
binding DNA and initiating single- and double-stranded DNA breaks, which results in 
cell cycle arrest or apoptosis.
203
 GO was marketed as an AML therapeutic from 2000 to 
2010 but was voluntary withdrawn from the market in June 2010 when postclinical trials 
showed an increasing number of deaths and a lack of benefit compared with other 
conventional cancer therapies.
204
 Currently, the combination of GO and other 
chemotherapeutics are under various stages of clinical investigations.
205
 
 
1.4.5 CD34  
 HSC antigen CD34 is a single transmembrane glycoprotein and belongs to the 
CD34 family of proteins.
206
 CD34 was first identified as a surface marker of immature 
lymphohematopoietic progenitor cells in 1984.
207
 Four years later, Berenson et al. 
reported that, following the transplantation of CD34
+
 human marrow cells, 
hematopoietic systems were able to reconstitute in lethally irradiated baboons.
208
 CD34 
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has been widely used as a surface marker for the identification of non
-
cancerous 
hematopoietic stem cells for over three decades
209
 and, more recently, has been 
identified as a CSC marker for multiple diseases (vide supra). Besides hematopoietic 
and leukemic stem and progenitor cells, CD34 is also widely expressed on the surface of 
vascular endothelial cells and mast cells.
209
 In spite of the functional importance of 
CD34, the crystal structure of this protein remains unsolved. As a result, the structure 
and function of CD34 is not as well studied as CD44. The extracellular domain of CD34 
contains a serine-, threonine- and proline-rich domain that is extensively glycosylated 
and sialylated.
210,211
 Moreover, a juxtamembrane stalk region, a cysteine-bonded 
globular domain, and a putative N-glycosylation site were also identified in the 
extracellular section of CD34.
206
 The most well-known intercellular binding partner of 
CD34 is L-selectin, which is a cellular adhesion molecule expressed on the surface of 
leukocytes.
212
 Other potential ligands of CD34 are also under exploration. In addition, 
each CD34 protein comprises a single transmembrane helix and a cytoplasmic domain 
that contains highly conserved phosphorylation sites and a C-terminal PDZ 
(postsynaptic density protein) binding motif.
210,213
 The PDZ binding motif of CD34 
recognizes Crk-like protein, which is an adaptor protein that further interacts with the N 
terminus of NHERF (Na
+
/H
+
 exchange regulatory cofactor) scaffolding proteins. The C 
terminus of NHERFs contains an ERM binding domain, which facilitates the indirect 
interaction of actin cytoskeleton with other binding partners of NHERF proteins.
214
 
CD34 has been proposed to be involved in enhancing proliferation,
213
 blocking 
differentiation,
215
 promoting lymphocyte adhesion,
211
 and the trafficking of 
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hematopoietic cells.
206,216
 Because of the ubiquitous expression pattern of CD44 on the 
surface of both cancerous and normal cells, it has not been utilized for drug delivery to 
CSCs. 
 
1.4.6 ABCB5  
 ATP-binding cassette sub-family B member 5 is a member of ABC transporter 
proteins that contains two transmembrane domains and two nucleotide binding 
domains.
217
 ABC transporter proteins are part of the p-glycoprotein family and are 
responsible for the transport of a large array of substrates across cellular membranes. 
Due to these characteristics, ABC transporter proteins are responsible for the multidrug 
resistance profiles of cancer cells due to their ability to export drugs from cells. ABCB5 
exists in two isoforms, α and β, and is a cell surface marker that is currently known to be 
expressed on skin cancer cells and is closely associated with the chemoresistance of 
malignantmelanoma
-
initiating cells (MMICs).
218
 
 3C2-1D12 is a monoclonal anti-ABCB5 antibody. Systematic administration of 
3C2-1D12 into nude mice revealed an increase in ADCC in ABCB5
+
 MMICs, as well as 
tumor-inhibitory effects.
107
 This anti-ABCB5 monoclonal antibody has not yet reached 
preclinical testing status. 
 
1.4.7 CD13  
 CD13 (alanine aminopeptidase N) is a 967-amino acid single-transmembrane 
peptidase, consisting of a small N terminus and a large C terminus that contains the 
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active site.
219
 CD13 is found ubiquitously in various organs, such as the kidneys, small 
intestines, and the liver. CD13 plays an important role in antigen processing for the 
immune response and is expressed in T and B cells as well as macrophages.
220
 CD13 has 
been reported as a diagnostic cell surface marker in liver CSCs.
94
 
 Ubenimex is a small molecule inhibitor of CD13. Ubenimex (bestatin) is a 
dipeptide isolated from Streptomyces olivoreticuli
221
 and is known to have antitumor 
effects through augmentation of the host immune system.
222,223
 Ubenimex is a 
competitive protease inhibitor and deters the growth of lung cancer and leukemic cell 
lines.
224,225
 A mechanism of action has been proposed by the co-crystallization of 
ubenimex with leukotriene A4 hydrolase (PDB 1HS6),
226
 which is structurally 
homologous to cell surface antigen CD13.
227
 Studies have shown that, in mouse 
xenograft models, the combination of CD13 inhibitor and cell proliferation inhibitor 
fluorouracil dramatically reduces tumor size, as well as tumor progression, as compared 
with either single agent therapy.
94
 Ubenimex is not under clinical investigation at the 
present time. 
 
1.4.8 CD123  
 CD123 is the α subunit of the interleukin-3 cell surface receptor. It has been 
elucidated as a CSC marker in AML
42
 but also has been identified as a marker of normal 
hematopoietic stem cells, where it plays an important role in proliferation.
228
 Structural 
information for CD123 is not well established. 
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 7G3 is a monoclonal anti-CD123 antibody. Targeting of CD123 by this antibody 
has been shown to significantly reduce CD34
+
/CD38
−
 AML CSC cell populations and 
tumor engraftment in NOD/SCID mice. However, the efficacy of the antibody in 
established AML disease treatment models is still limited, and optimization is required 
before this strategy is suitable for clinical investigations. The proposed mechanism of 
anti-CD123 antibodies (e.g., 7G3) includes the inhibition of AML CSC homing to bone 
marrow and prevention of activation of human CD123 by IL-3.
157
 To our knowledge, 
molecules of this class are not yet in clinical trials. 
 
1.4.9 CD47  
 The leukocyte surface antigen CD47 plays an important role in cell adhesion by 
acting as a platelet adhesion receptor.
229
 CD47 is widely expressed at low levels in many 
tissues and highly expressed on AML CSCs, where increased CD47 expression is 
indicative of poor prognosis.
51
 One functional ligand of CD47 is signal regulatory 
protein-α (SIRPα), which is expressed on phagocytes. The interaction between CD47 
and SIRPα activates a signal transduction cascade that results in the inhibition of 
phagocytosis.
230
 The ectodomain of CD47 was crystallized in 2008 (PDB 2JJS).
231
 
 Clone B6H12.2 is a monoclonal antibody that blocks the interaction between 
CD47 and SIRPα. It has been demonstrated that B6H12.2 enables phagocytosis of 
human AML CSCs in vitro and has therapeutic potential.
51
 In NOD/SCID mice, 
B6H12.2 treatment depleted AML cells in peripheral blood.
232
 In a preclinical in vivo 
mouse treatment model with high levels of engraftment, treatment with anti-CD47 
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antibodies resulted in the rapid clearance of AML and targeting of the CSC 
population.
51,232
 
 
1.5 Summary and conclusions 
 Numerous studies have reported the existence of tumor cell populations with 
abilities to self-renew, differentiate, and potently initiate tumorigenesis. These cell 
populations, termed cancer stem cells (CSCs), are strongly implicated in disease 
propagation and, if not addressed during drug therapy, can facilitate disease relapse. 
Consequently, there is a significant and unmet need to better characterize the unique 
biology of CSCs as well as develop therapies to eradicate them. CSC markers, which are 
macromolecules (e.g., proteins, carbohydrates, etc.) that are uniquely expressed on the 
surface or in the cytoplasm of CSCs, are essential for the isolation and characterization 
of CSC populations. Additionally, these CSC markers provide targets for the specific 
delivery of therapeutic molecules into CSCs. In this chapter, we reviewed those cell 
surface macromolecules that are presented on the surfaces of many tumor CSCs, 
described the unique chemical and structural features of the most common markers, and 
reported recent efforts to target CSC surface markers as part of drug delivery efforts. 
Clearly, the field of CSC biology is still in its infancy and even less advanced are efforts 
to target those cells with therapeutic molecules. However, given that the elimination of 
CSCs may result in significantly enhanced therapy outcomes in patients, the focus of 
cancer drug discovery scientists should shift, at least in part, to designing next 
generation drugs that target CSC populations. 
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Table 1.15. Alternative names of CSC surface markers that appear in this chapter. 
CSC marker Other common names 
Cancerous tissue 
where expressed 
A2B1 α2β1 Integrin; a2b1 integrin; CD49b Prostate 
A2B5 α2β5 Integrin; a2b5 integrin Brain 
ABCB5 ABCB5 P-gp; ATP-binding cassette sub-family B member 5 Melanoma 
ABCG2 ABC transporter G family member 2 Skin, bladder 
CD4 Leu-3; T4 ALL 
CD7 GP40; Leu-9; TP41 ALL 
CD9 
 
BTCC-1; DRAP-27; MIC3; MRP-1; TSPAN-29; 5H9 
antigen; p24 
ALL 
 
CD10 Atriopeptidase; CALLA; Enkephalinase; Neprilysin; SFE ALL 
CD13 Aminopeptidase N; Alanyl aminopeptidase; gp150; Lap1 Liver 
CD19 B-lymphocyte surface antigen B4; Leu-12 ALL 
CD24 
 
Small cell lung carcinoma cluster 4 antigen 
 
Breast, colorectal, 
ovarian, pancreatic 
CD25 Interleukin-2 receptor subunit alpha; TAC antigen; p55 AML 
CD29 
 
Integrin beta-1; Fibromectin receptor subunit beta; VLA-4 
subunit beta 
Breast 
 
CD32 Low affinity IgG Fc receptor II-b; CDw32; Fc-gamma RIIb AML 
CD33 Siglect
-
3; gp67 AML, ALL 
CD34 Hematopoietic progenitor cell antigen CD34 AML, ALL, CML 
CD38 ADP-ribosyl cyclase 1; cADPr hydrolase 1; T10 AML, ALL, CML 
CD44 
 
 
 
CDw44; Epican; ECMR-III; GP90 receptor; HUTCH-I; 
Heparan sulfate proteoglycan; Hermes antigen; PGP-1; 
Hyaluronate receptor 
 
AML, bladder, breast, 
colorectal, liver, 
ovarian, pancreatic, 
prostate 
CD45 
 
Receptor
-
type tyrosine
-
protein phosphatase C; Leukocyte 
common antigen; T200 
AML, liver 
 
CD47 
 
 
Leukocyte surface antigen CD47; antigenic surface 
determinant 
protein OA3; integrin
-
associated protein; MER6 
AML, bladder 
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Table 1.15. (Continued) 
 
CSC marker Other common names 
Cancerous tissue 
where expressed 
CD49f 
 
Integrin alpha-6; VLA-6 
 
Breast, colorectal, 
prostate 
CD71 Transferrin receptor protein 1; T9; p90 AML, breast, liver 
CD90 
 
Thy-1 membrane glycoprotein 
 
ALL, AML, breast, liver 
 
CD96 
 
T cell surface protein tactile; T cell-activated increased late 
expression protein 
AML 
 
CD110 
 
 
Thrombopoietin receptor; Myeloproliferative leukemia 
protein; 
Proto
-
oncogene c-Mpl 
ALL 
 
 
CD117 
 
 
Mast/stem cell growth factor receptor kit; Piebald trait 
protein; c-kit; p145; 
Tyrosine-protein kinase kit 
AML, ovarian 
 
 
CD133 
 
 
 
Prominin-1; antigen AC133; Prominin-like protein 1 
 
 
 
ALL, brain, breast, 
colorectal, liver, lung, 
melanoma, ovarian, 
pancreatic, prostate 
CD166 Activated leukocyte cell adhesion molecule Colorectal 
CD173 H2 Breast 
CD174 Lewis Y Breast 
CD176 Thomsen
-
Friedenreich antigen (TF) Breast, liver, lung 
CD201 Endothelial protein C receptor; PROCR; APC receptor Breast 
CK20 Cytokeratin-20; Protein IT Bladder 
CK5 
 
Type II keratin Kb5; Cytokeratin-5; 58 kDa cytokeratin; 
Keratin-5; Type II cytoskeletal 5 
Bladder 
 
CLL
-
1 
 
C-type lectin domain family 12 member A; DCAL-2; 
MICL 
AML 
 
CXCR4 
 
FB22; Fusin; HM89; LCR1; LESTR; NPYRL; SDF-1 
receptor; CD184; C-X-C chemokine receptor type 4 
Pancreatic 
 
Cytokeratin Keratin Breast 
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Table 1.15. (Continued) 
 
CSC marker Other common names 
Cancerous tissue where 
expressed 
EMA 
 
 
 
Epithelial membrane antigen; MUC-1; CD227; 
PEM; PUM; KL-6; H23AG; 
Episialin; Carcinoma
-
associated mucin; Breast 
carcinoma associated antigen DF3 
Bladder 
 
 
 
EpCAM 
 
 
CD326; GA733-2; KSA; KS1/4 antigen; ESA; 
EGP314; EGP-2; Adenocarcinoma-associated 
antigen; Cell surface glycoprotein Trop-1 
Breast, colorectal, liver, 
ovarian, pancreatic 
 
HLA
-
DR CD74; p33; Ia antigen-associated invariant chain AML 
L1CAM CD171 Brain 
Lin 
 
Cell lineage protein 
 
AML, bladder, breast, 
prostate 
OV6 
-
 Liver 
Sca
-
1 Stem cell antigen-1 Prostate 
SSEA
-
1 Stage-specific embryonic antigen-1; CD15 Brain 
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Chapter 2. Development of novel parthenolide analogues and evaluation of their 
anticancer activities 
 
2.1 Introduction 
 Sesquiterpene lactones are a large family of natural products that have broad 
therapeutic applications as anti-inflammatory, antimicrobial, antiviral and antitumor 
agents. Currently, there are over 5000 known natural sesquiterpene lactones from four 
different families;
233-236
 only three sesquiterpene lactones (and their adducts) have made 
it to clinical trials. These sesquiterpene lactones are thapsigargin, artemisinin, and 
parthenolide which were evaluated as antimalarial (artemisinin) and anticancer agents 
respectively (Thapsigargin and LC-1, Figure 2.1).
237
 
 
 
Figure 2.1 Structure of the three sesquiterpene lactones that have gone to clinical trials: 
thapsigargin, artemisinin, and the dimethylamino adduct of parthenolide. 
 
Parthenolide (PTL, 1) is a germacranolide sesquiterpene lactone from the 
feverfew plant Tanacetum parthenium, a known medical herb utilized for centuries.
238
 
  53 
Originally isolated by Sorm et al in 1961, PTL can comprise up to 1% of dried feverfew 
leaves.
239
 Out of all the natural products contained in feverfew leaves, PTL is the major 
natural product.
238
 Although known for many therapeutic uses, PTL has been 
predominately investigated as an anticancer agent against numerous cancer types, both 
in vitro and in vivo. Specifically, PTL has been tested against cervical cancer,
240
 
glioblastoma,
241
 breast cancer,
242,243
 leukemia,
234,244-246
 pancreatic cancer,
247
 prostate 
cancer,
248,249
 lung cancer,
250-252
 melanomas,
253-255
 and colon cancer.
256
  
Although the mechanism of anticancer activity of PTL is not fully elucidated, it 
has been demonstrated that PTL has strong NF-κB inhibition.233,257 It has been found 
that the NF-κB pathway is constitutively active or dysregulated in numerous disorders, 
including cancer.
237
 Currently, two mechanisms of inhibition have been elucidated for 
PTL: inhibition by preventing the phosphorylation and degradation of IκBα,235 and 
direct binding to the p65 transcription factor subunit.
258
 By binding directly to IκB 
kinase, the degradation of IκBα is prevented, sequestering the NF-κB transcription 
factors in the cytoplasm and activation of the pathway is prevented.
259
 Additionally, 
PTL can bind directly to the p65 subunit of the NF-κB transcription factors preventing 
DNA binding.
258
 
Recently, a publication by Jordan et al. has brought PTL into the forefront of 
anticancer therapeutic development.
246
 They discovered that PTL displayed selectivity 
against the AML stem cell population (CSC), but when dosed at the same concentration 
to normal hematopoietic stem cells, PTL had no cytotoxic effect.
246
 This selectivity was 
due to PTL inhibiting a constitutively active NF-κB pathway previously observed in 
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AML, but is regulated in normal hematopoietic cells.
260
 In contrast, Cytarabine, a first 
line chemotherapeutic for AML, displayed cytotoxicity against both AML cells and 
normal hematopoietic stem cells, while sparing the AML CSC population due to their 
quiescent nature.
246
 The ability for a chemotherapeutic to selectively target the CSC 
population versus the non-cancerous cell population is a rare characteristic that could 
potentially make chemotherapy less toxic to patients. Due to this unique trait, PTL is an 
attractive natural product for chemotherapeutic development. (for a comprehensive 
background on the CSC model please see Chapter 1). 
Unfortunately, PTL is not an ideal drug candidate. PTL suffers from poor 
bioavailability and modest in vitro cytotoxicity (low micromolar at best).
243,249
  Previous 
clinical trials investigating the extract of the feverfew plant yielded no detectable serum 
concentration of PTL in cancer patients.
261
 In a similar study in an in vivo mouse model, 
a maximum serum concentration of 0.169 µM was detected after an oral gavage of 
feverfew dose of 40 mg/kg, far below the required concentration to reach the IC50 which 
is in the low micromolar range.
261
 One way to address the bioavailability is to improve 
the aqueous solubility of PTL by conversion to a prodrug. One such compound 
(dimethylamino PTL, Figure 2.1) was found to be 1000-times more water soluble than 
PTL. However, the modest potency of the compound remains problematic.
248
 
In addition to development of a prodrug, structure activity relationships (SAR) 
have been previously investigated on sesquiterpene lactones in an effort to develop 
clinical candidates.
262-267
 Previous SAR studies of PTL have predominately focused on 
the exocyclic methylene (Figure 2.2).
234,240,268
 This is due to the ease of synthetic 
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accessibility of the exocyclic methylene, although it is the primary pharmacophore of 
PTL.
234,265,269,270
 To improve the bioavailability and cytotoxicity of PTL against cancer 
cells, we envisioned an SAR study against the various reactive functional groups of the 
molecule and to expand on the limited previous investigations in this regard (Figure 
2.3). This task will be accomplished through the development of a small library of PTL 
analogues. 
 
 
Figure 2.2 Previous SAR studies of the exocyclic methylene of Parthenolide. A. 
Modification of the exocyclic methylene via Michael addition of primary and secondary 
amines. Neelakantan et al. focused on aliphatic R groups, while Nasim et al. focused on 
aromatic R groups.
234,268
 B. Palladium-catalyzed arylation with aryl iodides to yield R-
alkylidene-γ-butyrolactones by Han et al.240 
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Figure 2.3 Functional group modifications investigated for their contributions to the 
anticancer activities of parthenolide (1, PTL) across a panel of cancer cell types.  
 
2.2 Research Objectives 
Using a semi-synthetic approach, we have developed a small library of PTL 
analogues (Figure 2.4). With this library of compounds, we elucidated the key structural 
features that confer PTL's cytotoxicity, and developed PTL analogues that possess less 
off-target cytotoxicity (toxicity to normal cells). Each compound was screened against 
nine cell lines to determine their IC50.  Described herein is the syntheses and biological 
evaluation of each PTL analogue, and its implications to the development of a more 
potent and selective antiproliferative agent.  
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Figure 2.4. Synthesized library of parthenolide analogues. 
 
2.3 Results and Discussion 
2.3.1 Synthesis of a Library of Parthenolide Analogues 
 The development of a library of PTL analogues began with the synthesis of 
dimethylamino prodrugs DMAPT (LC-1, 1a) and costunolide (CTL, 2) to deduce the 
importance of the exocyclic olefin (Scheme 2.1). A dimethylamino modification to the 
Michael acceptor allows increased water solubility while maintaining the activity due to 
elimination of the dimethylamino group within cells to the parent compound.
271,272
 
Following a published procedure to synthesize DMAPT, PTL was reacted with an 
excess of dimethylamine to afford 1a in 97% yield.
234
 CTL was refluxed with 
dimethylamine to yield 2a in 82% yield.
273
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Scheme 2.1 Synthesis of exocyclic olefin modified analogues 1a, 2a, and 3.  
 
In addition to the prodrugs, a reduced exocyclic methylene analogue of PTL, 
dihydroparthenolide (3) was synthesized as previously reported.
235,274,275
  PTL was 
hydrogenated in the presence of palladium on carbon under a hydrogen atmosphere. 
After 45 min complete reduction of the exocyclic methylene of PTL yielded 3 in 97% 
yield (Scheme 2.1), with no reduction of the C1-C10 olefin. We envisioned this PTL 
analogue would have no biological activity due to the removal of the Michael acceptor, 
the primary pharmacophore of PTL. 
The role of the C1-C10 olefin to the cytotoxicity profile of PTL was investigated 
by synthesizing compounds 4-6 (Scheme 2.2). In order to synthesize compounds 4 and 
5, without reduction of the exocyclic olefin, the PTL prodrug 1a was used. Initially, the 
reaction was attempted utilizing palladium on carbon in 1 atm of hydrogen gas, however 
no product was observed. The hydrogen pressure was increased to 50 psi with a Parr 
shaker which allowed for product formation; however, even after 5 days of shaking 
under pressure the reaction did not fully go to completion. Instead, the catalyst was 
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switched to platinum oxide (PtO2) under 50 psi of hydrogen gas to afford the reduced 
product 1b (99% yield) after 2 days. Reinstallation of the exocyclic methylene was 
achieved by reacting 1b with iodomethane to afford the quaternary iodonium salt. 
Heating of this intermediate with deionized water promoted Hofmann elimination 
yielding a mixture of diastereomers 4 and 5. Currently, the separation of these two 
diastereomers by HPLC is underway to provide ample material for testing and accurate 
reaction yeild. Previously, our lab separated a small portion of 4 and 5 by HPLC and 
crystallized diastermer 5. X-ray analysis allowed us to assign the relative 
stereochemistry of the methyl group (Appendix 1). Absolute stereochemistry was 
assigned due to the rest of the stereochemistry of PTL was known. 
 
 
Scheme 2.2. Synthesis of C1-C10 olefin modified PTL analogues. A. Hydrogenated C`-
C10 diastereomers 4 and 5. B. Attempted photoisomerization of PTL to provide Z-
isomer 6. 
 
In addition to eliminating the C1-C10 olefin, the stereochemistry of the C1-C10 
olefin was investigated. Previously reported syntheses of the Z-isomer of PTL (6, 
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Scheme 2.2) have been accomplished by photoisomerization using uv light radiation at 
254 nm.
274,276
 After multiple attempts, this method of isomerization could not be reliably 
executed in our hands. Instead we acquired the Z-isomer of PTL as a by-product during 
the synthesis of melampomagnolide B (7, Scheme 2.3). During the allylic oxidation of 
the C1-C10 olefin, a rotation of the vinyl methyl group must occur for the final [2,3]-
sigmatropic rearrangement to occur. Instead of the sigmatropic shift occurring, selenium 
is eliminated yielding the Z-isomer of PTL (6) as a byproduct in 4% yield. We used this 
material for screening. 
Oxidative modifications to the C1-C10 allylic metyl group of PTL were also 
investigated. According to an established protocol, PTL was reacted with selenium 
dioxide and tert-butyl hydroperoxide in an allylic oxidation of the C1-C10 olefin to 
yield melampomagnolide B (7, Scheme 2.3) in 74% yield.
277,278
 Compound 7 was then 
reacted with dimethylamine to produce 7a in 97% yield, protecting the exocyclic olefin. 
Compound 7a was then reacted with palladium on carbon under 50 psi of hydrogen gas 
to reduce the C1-C10 olefin. Deprotection of the exocyclic olefin was achieved to yield 
8 via a Hofmann elimination as previously described for preparation of 4 and 5.  
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Scheme 2.3. Synthesis of melampomagnolide analogues of PTL. Melampomagnolide B 
(7) was synthesized as previously described.
278,279
 
 
The guaianolide analogues (Figure 2.5) were provided by co-worker Dan Wang 
(9 and 10). The 5-7-5 ring structure of guaianolide was achieved by reacting PTL with 
boron trifluoride diethyl etherate, via reaction of the C1-C10 olefin with the epoxide, 
yielding analogues 9 and 10 as previously described.
280,281
 
 
 
Figure 2.5 Synthesized rearranged guaianolide analogues of Parthenolide. 
 
In addition to structural modifications of PTL, the fumarate salts of all 
dimethylamino analogues of the exocyclic methylene (1a, 2a, 7a, and 9) were 
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synthesized to afford greater water solubility (Scheme 2.4). Generally, the 
dimethylamino compounds were reacted with fumaric acid to afford 11-14, in high 
yields (range 82% - quant). 
 
 
Scheme 2.4. Synthesis of fumarate salt analogues of PTL dimethylamino prodrugs. 
 
2.3.2 Biological Evaluation of Parthenolide Analogues 
 The synthesized analogues of PTL were evaluated for their cytotoxicity in nine 
cell lines to probe the effect of structural modification on cellular cytotoxicity profiles 
(Table 2.1). Cancer cell lines investigated were DU-145 (prostate cancer), CCRF-CEM 
(acute lymphoblastic leukemia), HL-60 (promyelocytic leukemia), HeLa (cervical 
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cancer), MCF-7 (breast cancer), GBM6 (glioblastoma multiforme), U-87MG 
(glioblastoma multiforme), and NCI-ADR-RES (multidrug-resistant ovarian 
cancer
273,282
). Vero cells (African green monkey epithelial kidney cells) were utilized to 
gauge cytotoxicity against normal cells. Each compound evaluated for antiproliferative 
activity was verified to be ≥ 95% pure by HPLC. Stock solutions were made by 
dissolving compounds into molecular biology grade DMSO and were stored at -20 °C. 
Cells were plated in 96 well plates and allowed to incubate for 24 hours. The next day, 
plates were dosed with molecules, each concentration dosed in triplicate, and then 
incubated for 48 hours. The plates were stained with Alamar Blue® metabolic viability 
reagent during the final 1-3 hours of dosing. Reaction time with Alamar blue® varied 
between cell type, but fluorescent readout was only accepted above 1000 AFU. For 
HeLa, DU-145, U-87MG, MCF-7 and Vero cell lines, deoxidative metabolism of the 
reagent was observed to be rapid and required an incubation time of 1.5 hours. HL-60 
cells metabolized Alamar Blue® at a much slower rate requiring a 3 h incubation time to 
observe fluorescence above 1000 AFU. For all remaining cell lines, an incubation time 
of 2 h for Alamar Blue® was used. Data collected was normalized by subtracting blank 
wells (contained no cells) and dividing by control wells (cells with no drug). Normalized 
values were graphed using GraphPad prism using a sigmoidal dose-response equation to 
determine the IC50. Sigmoidal dose-response curves were generated in triplicate to 
determine the average IC50 and standard deviation. PTL was dosed above and below its 
IC50 as a control for each plate.  
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2.3.2.1 Biological Evaluation of Parthenolide, Costunolide, and Reduced 
Parthenolide 
We found that PTL conveys modest low micromolar cytotoxity against six of the 
eight cancer cell lines tested (DU-145, IC50 = 8.9 ± 4.6 µM; CCRF-CEM, IC50 = 4.7 ± 
1.6 µM; U-87MG, IC50 = 5.8 ± 2.3 µM; GBM6, IC50 = 3.4 ± 1.1 µM; HL-60, IC50 = 9.3 
± 3.8 µM; MCF-7, IC50 = 9.7 ± 2.8 µM Table 2.1). HeLa and NCI/ADR-RES cell lines 
required higher concentrations to achieve an IC50 (HeLa, IC50 = 44.1 ± 6.4 µM; 
NCI/ADR-RES, IC50 = 57.6 ± 8.9 µM). PTL also conveyed the same cytotoxicity 
against the normal Vero cell line (IC50 = 12.4 ± 0.6 µM) when compared to the cancer 
cell lines, reinforcing the need for a PTL analogue that can spare normal cells. Previous 
studies of PTL against cell lines MCF-7, HL-60, U-87MG, and HeLa were in general 
agreement withour data, revealing low micromolar inhibitory activity, with some 
variability resulting from different incubation times and methods of viability 
measurements.
281,283,284
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Biological evaluation of CTL (2) demonstrated that the loss of the epoxide from 
PTL was highly tolerated across five cancer cell lines (IC50 for DU-145, CCRF-CEM, 
U-87MG, and GBM6 = 2.3 – 9.6 µM vs. PTL = 3.4 – 8.9 µM; IC50 for NCI/ADR-RES 
= 44.8 ± 7.4 µM vs. PTL = 57.6 ± 8.9 µM). Loss of the epoxide was not tolerated in the 
two remaining cancer cell lines evaluated (HL-60 35.4/37.8 µM vs. PTL = 9.3 ± 3.8 
µM; MCF-7, 16.7/14.3 µM vs. PTL = 1.4/6.7 µM) indicating a need for this functional 
group for maintaining activity to the level of PTL. Additionally, loss of activity against 
Vero cells (IC50 = 25.7 ± 0.9 µM vs. PTL = 12.4 ± 0.6 µM). Costunolide was previously 
reported to inhibit growth of DU-145 cells at IC50 = 4.8 µM, verifying our observation 
of IC50 = 7.5 ± 3.1 µM.
285
 HL-60 results were consistent with previous reports of CTL 
being dosed up to 8 µM and greater than 97% cell viability observed.
286
 
Reduced PTL analogue 3 was observed to be biologically inactive (IC50 > 500 
µM) in all cell lines tested, indicating that the exocyclic olefin must remain intact for 
biological activity of PTL.  These results are consistant with previous reports of 
biological activity of reduced PTL in other cell lines as well as antiviral 
activity.
234,275,287
 Additionally, complete loss of activity of reduced PTL was observed 
when dosed to primary leukemia cells.
234
 
 
2.3.2.2 Biological Evaluation of C1-C10 Olefin Modified Parthenolide Analogues 
 Analogues with modifications to the C1-C10 olefin (compounds 4-6) were 
highly tolerated and demonstrated similar biological activity to the parent compound, 
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PTL (Table 2.2). Diastereomers 4 and 5 were equipotent to PTL in all cancer cell lines 
tested (DU-145, CCRF-CEM, U-87MG, and GBM6; IC50 for 4 and 5 = 1.6 – 7.7 ± 0.4 – 
2.8 µM vs. PTL = 3.4 – 8.9 ± 1.1 – 4.6 µM). Compounds 4 and 5 also demonstrated the 
same cytotoxicity against the normal Vero cell line (IC50 = 13.9 ± 2.2 and 12.1 ± 3.3 
µM, respectively) when compared to PTL (IC50 = 12.4 ± 0.6). Biological testing in 
HeLa, MCF-7, NCI/ADR-RES, and HL-60 still need to be completed for analogues 4 
and 5.  
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 Similar to diastereomers 4 and 5, the Z-olefin isomer of PTL, compound 6, has 
been evaluated for anticancer activity. Analogue 6 demonstrated the same biological 
activity when compared to the parent compound PTL in cancer cell lines DU-145, 
CCRF-CEM, U-87MG, and HL-60 (IC50 for 6 = 2.2 – 9.1 ± 1.0 – 4.4 µM vs. IC50 for 
PTL = 4.7 – 9.3 ± 1.6 – 4.6 µM respectively) demonstrating that the orientation of the 
vinyl methyl group is not vital to the anticancer activity in these cell lines. In the 
chemoresistant cell line NCI/ADR-RES 6 gained activity when compared to PTL (IC50 
for 6 = 9.4 ± 2.1 vs. PTL = 57.6 ± 8.9). GBM6, HeLa, and Vero cell lines still require 
testing of 6 in triplicate. From these observations of C1-C10 modified analogues, the 
presence of the C1-C10 olefin is not vital to the anticancer activity of PTL. 
 
2.3.2.3 Biological Evaluation of Oxidative Modified Parthenolide Analogues 
Melampomagnolide B (7) was found to have similar cytotoxicity to PTL in the 
cancer cell lines DU-145, CCRF-CEM, HL-60, HeLa, and MCF-7 (IC50 for 7 = 14.1 ± 
5.7, 5.5 ± 1.2, 7.5 ± 3.0, 36.1 ± 3.2, and 9.5 ± 1.9 µM vs. PTL = 8.9 ± 4.6, 4.7 ± 1.6, 9.3 
± 3.8, 44.1 ± 6.4, and 1.4,6.7 µM). Unfortunately 7 also conveyed the same cytotoxicity 
for normal Vero cells as PTL (IC50 for 7 = 15.6 ± 3.5 µM vs. PTL = 12.4 ± 0.6 µM) 
indicating that oxidation of the vinylogous methyl group does not help with off-target 
biological activity. Loss of activity was observed for 7 in the glioblastoma cell line U-
87MG (IC50 for 7 = 16.3 ± 6.8 µM vs. PTL = 5.8 ± 2.3 µM). Additional testing is still 
required for GBM6 and NCI/ADR-RES. Data from our screening in leukemia cell lines 
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matches previous reported IC50 results observed from dosing 7 to primary leukemia 
cells.
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Reduction of the C1-C10 olefin of Melampomagnolide B (7) was also performed 
to investigate if the orientation of the alcohol had an impact on the anticancer activity of 
PTL. After hydrogenation, the two diastereomers were tested as a mixture (8). A loss of 
activity in DU-145 and U-87MG cells was observed for 8 (IC50 = 26.7 ± 6.5, and 26.8 ± 
2.3 µM, respectively) when compared to PTL (IC50 = 8.9 ± 4.6 and 5.8 ± 2.3 µM, 
respectively). Data has been collected for CCRF-CEM, GBM6, and HL-60 but not yet in 
triplicate. HeLa, MCF-7, NCI/ADR-RES and Vero all still require triplicate evaluation 
of 8. 
 
2.3.2.4 Biological Evaluation of Rearranged Guaianolide Parthenolide Analogues 
Rearranged guaianolide analogue 9 demonstrated equipotent cytotoxicity in three 
cancer cell lines (DU-145, CCRF-CEM, and HL-60: IC50 = 14.8 ± 4.0, 5.2 ± 1.8, and 7.1 
± 1.3 µM respectively) when compared to PTL (DU-145, CCRF-CEM, and HL-60: 
PTL = 8.9 ± 4.6, 4.7 ± 1.6, and 9.3 ± 3.8 µM respectively). It was observed with the 
glioblastoma cell lines (U-87MG and GBM6), as well as the metastatic breast cancer 
cell line MCF-7, that a higher concentration were required to achieve IC50 when 
compared to PTL (IC50 for U-87MG,  GBM6, and MCF-7 for 9: 16.2 ± 3.6, 8.7 ± 0.6, 
9.6 ± 1.0 µM vs. PTL = 5.8 ± 2.3, 3.4 ± 1.1, and 1.4/6.7 µM,  respectively). 
Interestingly, 9 also demonstrated less cytotoxicity against the normal Vero cell line 
(IC50 = 36.1 ± 9.4 µM vs. PTL = 12.4 ± 0.6 µM) 
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Rearranged guaianolide analogue 10 was also found to have similar cytotoxicity 
in three cancer cell lines (DU-145, CCRF-CEM, and HL-60: IC50  = 13.9 ± 3.7, 4.8 ± 
1.5, 11.6 ± 0.2 µM respectively) when compared to PTL (DU-145, CCRF-CEM, and 
HL-60: PTL = 8.9 ± 4.6, 4.7 ± 1.6, and 9.3 ± 3.8 µM respectively). Similar to 9, 
analogue 10 lost activity against the glioblastoma cell lines U-87MG and GBM6 (IC50 = 
29.3 ± 3.0, and 8.4 ± 1.8 µM respectively) when compared to PTL (IC50 = 5.8 ± 2.3 and 
3.4 ± 1.1 µM  respectively). A decrease in activity was also observed in the breast 
cancer cell line MCF-7 (IC50 = 25.0 ± 4.3 µM) as compared to PTL (IC50 = 1.4, 6.7 
µM). Analogue 10 also showed the lowest cytotoxicity against the normal cell line Vero 
(IC50 = 54.5 ± 3.0 µM) out of all the other analogues when compared to PTL (IC50 = 
12.4 ± 0.6 µM). Triplicate data has not been completed yet for HeLa and NCI/ADR-
RES.  
 
2.3.2.5 Biological Evaluation of Dimethylamino Fumarate Parthenolide Analogues. 
Dimethylamino furmarate salts were highly tolerated as modifications of PTL.  
LC-1 fumarate salt (11) displayed the same cytotoxicity against all the cancer cell lines 
when compared to PTL (IC50 for 11 = 1.9 – 63.5 ± 0.4 – 11.8 µM vs. IC50 for PTL = 3.4 
– 44.1 ± 1.6 – 6.4 µM). Unfortunately, the same cytotoxicity was observed for 11 
against the normal Vero cell line (IC50 = 15.6 ± 7.8 µM vs. PTL = 12.4 ± 0.6 µM). 
Although not primary leukemia cell lines themselves, HL-60 and CCRF-CEM leukemia 
cell lines match previous data performed in primary leukemia cell lines.
234
 Although not 
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tested in vivo for our studies, LC-1 has been previously investigated in pancreatic and 
prostate murine models resulting in tumor suppression.
288,289
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CTL fumarate salt 12 only retained the same activity as 11 in the leukemia cell 
line CCRF-CEM and normal Vero cells (CCRF-CEM and Vero IC50s for 12 = 6.6 ± 2.5 
and 21.1 ±1.2 µM vs. 11 =1.9 ± 0.4 and 15.6 ± 7.8 µM respectively). 12 lost activity 
against seven other cancer cell lines (IC50 for DU-145, U-87MG, HL-60, HeLa, MCF-7, 
NCI/ADR-Res, and GBM6 = 6.6 -118 ± 0.9 - 18 µM vs. 11 (IC50 = 3.5 – 63.8 ± 0.4 – 
11.8 µM). Previous DU-145 cytotoxicity data for only the dimethylamino compound 2a, 
and not the fumarate salt was available. Our findings agreed with the previous DU-145 
anticancer data.
273
  
The Melampomagnolide B fumarate salt 13 is currently under additional 
biological evaluation to determine its IC50 values in all nine cell lines. It has been 
elucidated that it has lower cytotoxicity in U-87MG, HL-60, and MCF-7 (IC50 = 28.3 ± 
2.3, 36.2 ± 6.1, and 16.7 ± 0.9 µM vs. PTL = 5.8 ± 2.3, 9.3 ± 3.8, and 1.4, 6.7 
respectively). Compound 13 was found to be equipotent as PTL in the glioblastoma cell 
line GBM6 (IC50 for 13 = 5.8 ± 1.2 vs. PTL = 3.4 ± 1.1). 
The dimethylamino fumarate salt of guaianolide 9 (14) was not as well tolerated 
as other dimethylamino fumarates. Guaianolide fumarate salt 14 lost activity against all 
cell lines tested to date (IC50 for DU-145, CCRF-CEM, U-87MG, HL-60, and GBM6 = 
27.8 – 77.5 ± 7.3 – 10.4 µM vs. PTL = 3.4 – 9.3 ± 1.1 – 4.6 µM; NCI/ADR-RES = 74.5 
µM vs. PTL = 57.6 ± 8.9 µM). In HeLa cells 100% cell viability was not achievable 
with 500 µM being the largest concentration dosed. The extrapolated IC50 value was > 
  78 
250 µM. Additionally, activity was also lost against the normal Vero cell line (IC50 for 
14 = 48.7 ± 5.9 µM vs. PTL = 12.4 ± 0.6 µM). 
 
2.4 Conclusion and Future Direction 
 In summary, we have synthesized a library of PTL analogues to elucidate the 
importance of various functional groups to its cytotoxicity profile. The modified 
functional groups of PTL included alterations to the exocyclic olefin, C1-C10 olefin, the 
vinyl methyl group, as well as loss of the epoxide. In addition, rearranged 5-7-5 
guainanolide analogues were synthesized to observe the importance of the ring structure 
of PTL to its cytotoxicity profile. Dimethylamino prodrugs were synthesized to address 
the water solubility issues of PTL and evaluated as fumarate salts for their biological 
activity. The only modification to completely ablate activity of PTL across all cell lines 
was removal of the exocyclic olefin, the primary pharmacophore of PTL.  
Modifications to the C1-C10 olefin were tolerated across all cell lines tested for 
analogues 4-6 indicating that alteration or complete removal of the internal olefin of 
PTL has no effect on the biological activity. Oxidative modifications to the vinyl methyl 
group were also highly tolerated with slight loss of activity observed in the glioblastoma 
cell line U-87MG. Tolerance of the installation of the allylic alcohol can allow for 
further modifications to this site to prepare PTL probe compounds and additional 
analogues. Dimethylamino fumarate salt analogues 11-14 all displayed low cytotoxicity 
within 5-fold of PTL against the cancer cell lines tested, confirming that the 
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dimethylamino prodrug of PTL is a viable modification to improve water solubility 
while retaining biological activity.  
The rearranged guaianolide analogues 9 and 10 demonstrated the most 
interesting biological activity of all the PTL analogues. Although analogues 9 and 10 
displayed similar activity when compared to PTL in most cancer cell lines (except U-
87MG, 10 was 6-fold less potent than PTL), the greatest finding was a loss in activity 
against the normal cell line Vero. Both rearranged PTL analogues 9 and 10 had up to a 
5-fold loss in activity against Vero cells, indicating that the more ridged 5-7-5 
guaianolide ring structure was not as cytotoxic to normal cells. From these results we 
can conclude that the guaianolide ring structure should serve as a new basis for further 
SAR studies.  Other future direction for this SAR could include modifications to the 
butyrolactone, as well alterations in ring sizes for new potential clinical leads. Re-
synthesis and purification of analogues 4, 5 and 8 to finish biological testing is currently 
underway. 
 
2.5 Experimental 
2.5.1 General 
All reactions were performed under an anhydrous nitrogen atmosphere unless 
otherwise noted.  Parthenolide was purchased from Enzo Life Sciences and repurified by 
SiO2 chromatography prior to biological studies. Costunolide was purchased from 
Tocris Biosciene (Boston, MA) and was used without further purification.  Commercial 
grade reagents (Aldrich, Acros, Alfa Aesar) were used without further purification 
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unless otherwise noted.  Tetrahydrofuran and dichloromethane were rendered anhydrous 
by passing through the resin column of a solvent purification system. Benzene was 
purified by distillation over calcium hydride. Methanol and N,N-dimethylformamide 
were purchased as anhydrous solvent. High pressure hydrogenation reactions were 
performed in a Parr hydrogenation apparatus (Moline, IL; model # 3916).  All reactions 
were monitored by thin-layer chromatography (TLC) using silica gel 60-F254 TLC plates 
(Merck), and visualized using cerium ammonium molybdate stain. Silica gel 
chromatography was performed using a Teledyne-Isco Combiflash Rf 200 instrument 
using Redisep Rf Gold High-Performance silica gel columns (Teledyne-Isco). HPLC 
purification was performed using an Agilent 1200 series instrument equipped with a 
Zorbax (Agilent) preparatory column (21.2 x 250 mm, 7 µm). Analysis of compound 
purity was conducted on the aforementioned HPLC, using a Zorbax analytical column 
(4.6 x 150 mm, 5 µm). Nuclear magnetic resonance (NMR) spectroscopy employed a 
Bruker Avance instrument operating at 400 MHz (for 
1
H) and 100 MHz (for 
13
C) at 
ambient temperature. Internal solvent peaks were referenced in each case.  Mass spectral 
data was obtained from the University of Minnesota Department of Chemistry Mass 
Spectrometry lab, employing a Bruker BioTOF II instrument. 
 
2.5.2 Synthesis of Parthenolide Analogues 
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Dimethylamino Parthenolide 1a.  
Known compound 1a was prepared by the method of Neelakantan et al.
234
 Parthenolide 
(16.90 mg, 0.07 mmol) was dissolved in methanol (4 mL) and dimethylamine was added 
(0.10 mL, 0.20 mmol). The reaction was allowed to stir for 5 h at rt, and then 
concentrated in vacuo to yield compound 4 (19.90 mg, 97%) as an off white crystalline 
solid. 
1
H NMR (400 MHz, CDCl3) δ = 5.19 (dd, J = 12.3, 3.8 Hz, 1H), 3.81 (t, J = 9.0 
Hz, 1H), 2.78 – 2.68 (m, 2H), 2.62 (dd, J = 13.2, 4.8 Hz, 1H), 2.45 – 2.31 (m, 2H), 2.25 
(s, 6H), 2.22 (s, 1H) , 2.21 – 2.01 (m, 5H), 1.68 (t, J = 1.2 Hz, 3H), 1.66 – 1.57 (m, 1H), 
1.28 (s, 3H), 1.21 (td, J = 13.0, 5.8 Hz, 1H). 
13
C NMR (100 MHz, CDCl3) δ = 176.6, 
134.8, 125.2, 82.3, 66.7, 61.6, 57.8, 48.0, 46.6, 46.3, 46.3, 41.2, 36.8, 30.1, 24.2, 17.3, 
17.1. MS-ESI
+
 m/z [M+H] calcd for C17H28NO3: 294.2, found: 294.2. MS-ESI
+
 m/z 
[M+Na] calcd for C17H27NO3Na: 316.1, found: 316.2. 
 
 
Dimethylamino Costunolide 2a 
The known compound 2a was prepared by as described by Srivastava et al.
273
  
Costunolide (10.0 mg, 0.04 mmol) was dissolved into ethanol (15 mL). An excess of 
dimethylamine (0.1 mL, 0.2 mmol) was added and the reaction was refluxed at 90 °C 
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overnight. The reaction was concentrated in vacuo after reacting for 12 h. The crude 
product was purified by flash chromatography over SiO2 (gradient 0-10% methanol in 
dichloromethane) to yield compound 2a (9.8 mg, 82%) as an off-white crystalline solid. 
1
H NMR (400 MHz, CDCl3) δ 4.82 (dd, J = 11.5, 4.5 Hz, 1H), 4.66 (d, J = 9.7 Hz, 1H), 
4.55 (t, J = 9.3 Hz, 1H), 2.74 (dd, J = 13.2, 5.1 Hz, 1H), 2.60 (dd, J = 13.2, 4.8 Hz, 1H), 
2.39 – 2.29 (m, 2H), 2.27 (s, 6H), 2.25 – 2.12 (m, 2H), 2.12 – 1.91 (m, 4H), 1.68 (d, J = 
1.4 Hz, 3H), 1.64 – 1.54 (m, 1H), 1.40 (s, 3H), 1.25 (s, 1H). 13C NMR (100 MHz, 
CDCl3) δ 177.7, 140.6, 137.2, 127.5, 127.0, 81.5, 58.1, 51.3, 46.3, 46.2, 41.2, 39.7, 28.5, 
26.3, 17.4, 16.3. MS-ESI
+
 m/z [M+H] calcd for C17H28NO2: 278.2, found: 278.2. 
 
 
Reduced Parthenolide 3 
Known compound 3 was prepared by the method of Govindachari et al.
282
 Parthenolide 
(13.50 mg, 0.054 mmol) and palladium on carbon (14.20 mg, 0.13 mmol) were added to 
a flask and ethanol (10 mL). The reaction was placed under 1 atm of H2, and allowed to 
stir for 45 mins. Upon completion, the reaction was filtered through celite and the 
solvent was removed in vacuo. The product was purified by flash chromatography over 
SiO2 (10-50% ethyl acetate in hexanes gradient) to yield compound 3 (13.30 mg, 97% 
yield). 
1
H NMR (400 MHz, CDCl3) δ = 5.19 (dd, J = 11.8, 1.8 Hz, 1H), 3.81 (t, J = 9.1 
Hz, 1H), 2.70 (d, J = 9.0 Hz, 1H), 2.46 – 2.22 (m, 3H), 2.16 (m, 2H), 2.05 (t, J = 12.3 
Hz, 1H), 1.95 – 1.79 (m, 3H), 1.70 (s, 3H), 1.68 – 1.35 (m, 3H), 1.29 (s, 3H). MS-ESI+ 
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m/z [M+H] calcd for C15H23O3Na: 273.1, Found: 273.1. MS-ESI
+
 m/z [M+H] calcd for 
C15H22O3K: 289.1, found: 289.1.  
 
 
Reduced C1-C10 Olefin of Dimethylamino Parthenolide 1b 
Compound 1a (29.10 mg, 0.10 mmol) was dissolved into ethyl acetate, and PtO2 (29.50 
mg, 0.28 mmol) was added. The reaction was placed under an atmosphere of H2 (50 psi) 
and the reaction was shook for 2 days with a Parr shaker. The reaction was then filtered 
through a celite plug and washed with ethyl acetate (5 × 5 ml) and dichloromethane (5 x 
4 ml). The solvent was removed in vacuo to yield compound 1b (29.30 mg, 99%) as a 
white crystalline solid. 1H NMR (400 MHz, CDCl3) δ = 3.82 (t, J = 9.4 Hz, 1H), 3.00 (d, J = 
9.6 Hz, 1H), 2.72 (dd, J = 12.9, 4.0 Hz, 1H), 2.58 (dd, J = 12.9, 5.0 Hz, 1H), 2.37 (m, 
2H), 2.25 (s, 6H), 2.15 (m, 2H), 1.73 (m, 2H), 1.66 – 1.52 (m, 2H), 1.49 (s, 3H), 1.47 – 
1.36 (m, 3H), 1.10 (m, 2H), 0.88 (d, J = 6.4 Hz, 3H). 
13
C NMR (100 MHz, CDCl3) δ= 
177.1, 80.8, 76.7, 66.6, 61.1, 58.2, 46.2, 45.6, 44.3, 36.6, 35.7, 30.8, 27.6, 25.7, 21.2, 
20.5, 19.0. HRMS-ESI
+
 m/z [M+H] calcd for C17H30NO3: 296.2220, found: 296.2229. 
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 and  
C1-C10 Reduced PTL Analogues 4 and 5 
Compound 1b (28.70 mg, 0.01 mmol) was dissolved into THF (2 ml) and iodomethane 
was added in excess (0.10 ml, 1.60 mmol). The reaction was allowed to stir at rt for 20 
h. The solvent and excess iodomethane was removed in vacuo resulting in 30.6 mg of 
yellowish solid. Distilled water (10 mL) was added and the reaction was heated to 45 
°C. Complete solvation of the yellowish material resulted within minutes of heating. The 
reaction was allowed to stir with heating for 3 h, and then solvent was removed in 
vacuo. Saturated NaHCO3 aqueous solution (5 mL) was added to the reaction mixture, 
and the product was extracted with DCM (3 × 20 mL). The combined organic layers 
were washed with brine (20 mL), and dried with Na2SO4. The reaction was purified by 
flash chromatography over SiO2 (10%-50% ethyl acetate in hexanes gradient) to yield 
12.3 mg of crude product.  HPLC separation and characterization is currently underway. 
 
 
Cis Parthenolide 6 
Previously reported synthesis of cis parthenolide were attempted but could not be 
replicated in my hands.
274,279
 Cis parthenolide was isolated as a side product from 
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synthesis of melampomagnolide B (7). Crude material was purified by SiO2 (gradient 10 
– 50% ethyl acetate in Hexanes) to yield compound 6 (7.90 mg, 4% yield) as a white 
crystalline solid. 
1
H NMR (400 MHz,CDCl3) δ = 6.24 (d, J = 3.5 Hz, 1H), 5.53 (d, J = 
3.2 Hz, 1H), 5.33 (t, J = 7.3 Hz, 1H), 3.83 (t, J = 9.3 Hz, 1H), 2.90 (d, J = 9.4 Hz, 1H), 
2.77 (M, 1H), 2.50 – 2.18 (m, 3H), 2.10 (m, 3H), 1.71 (s, 3H), 1.69 – 1.58 (m, 1H), 1.53 
(s, 3H), 1.07 (t, J = 12.1 Hz, 1H). MS-ESI
+
 m/z [M+Na] calcd for C15H20NaO: 271.1, 
Found: 271.1. MS-ESI
+
 m/z [M+K] calcd for C15H20KO: 287.1, found: 287.1. 
 
 
Melampomagnolide B (7)  
Known compound 7 was prepared by the method of Nasim et al.
277,278
 Parthenolide (49 
mg, 0.20 mmol) and selenium dioxide (22 mg, 0.20 mmol) were suspended in anhydrous 
dichloromethane (15 mL) and t-BuOOH (0.32 mL, 3.33 mmol, 70% in H2O) and 
refluxed at 40 °C for 4.5 h. The reaction mixture was cooled to rt, and water (15 mL) 
was added to the reaction. The crude material was extracted with DCM (3 × 15 mL). 
The combined organics were dried over Na2SO4. The solvent was then removed in 
vacuo, and the product was purified by chromatography over SiO2 (gradient 10-50% 
ethyl acetate in hexanes) to yield compound 3 (38.60 mg, 74%) as an off-white 
crystalline solid. 
1
H NMR (400 MHz, CDCl3) δ = 6.25 (d, J = 3.5 Hz, 1H), 5.66 (t, J = 
8.3 Hz, 1H), 5.55 (d, J = 3.2 Hz, 1H), 4.23 – 4.04 (q, J = 12.6 Hz, 2H), 3.86 (t, J = 9.3 
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Hz, 1H), 2.92 – 2.76 (m, 2H), 2.42 (s, 2H), 2.37 – 2.11 (m, 3H), 1.74 – 1.61 (m, 1H), 
1.56 (s, 3H), 1.18 – 1.04 (m, 1H). 13C NMR (100 MHz, CDCl3) δ= 169.6, 139.7, 139.0, 
127.7, 120.4, 81.3, 66.0, 63.5, 60.2, 43.0, 37.0, 25.7, 24.1, 23.8, 18.2 ppm; MS-ESI
+
 m/z 
[M+Na] calcd for C15H20NaO4: 287.1, found: 287.1. 
 
 
Dimethylamino adduct of Melampomagnolide B (7a) 
Melampomagnolide B, 7, (32.50 mg, 0.10 mmol) was dissolved in methanol (4 ml) and 
dimethylamine was added (0.10 mL, 0.20 mmol). The reaction was allowed to stir 
overnight, and was then concentrated in vacuo to yield compound 7a (32.70 mg 86%) as 
a white solid. 
1
H NMR (400 MHz, CDCl3) δ = 5.59 (t, J = 7.9 Hz, 1H), 4.10 (q, J = 13.0 
Hz, 2H), 3.85 (t, J = 9.2 Hz, 1H), 2.80 (d, J = 9.4 Hz, 1H), 2.73 (dd, J = 12.9, 5.1 Hz, 
1H), 2.61 (dd, J = 12.9, 5.4 Hz, 1H), 2.51 – 2.35 (m, 4H), 2.25 (m, 2H), 2.21 (s, 6H), 
2.12 (m, 2H), 1.59 (m, 1H), 1.52 (s, 3H), 1.07 (t, J = 11.4 Hz, 1H). 
13
C NMR (100 MHz, 
CDCl3) δ = 177.0, 141.1, 127.2, 81.6, 77.5, 66.0, 64.1, 60.0, 57.7, 45.7, 44.3, 42.2, 37.1, 
27.5, 25.8, 23.8, 18.0. HRMS-ESI
+
 m/z [M+H] calcd for C17H28NO4: 310.2013, found: 
310.1999. 
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Reduced C1-C10 olefin of Melampomagnolide B 8 
Compound 7a (46.90 mg, 0.15 mmol) was dissolved into ethyl acetate (10 mL), and 
10% palladium on carbon (46.30 mg, 0.44 mmol) was added to the reaction mixture. 
The reaction was put under an atmosphere of 50 psi hydrogen gas, and shook for 5 days. 
The reaction mixture was filtered through a celite plug and washed with ethyl acetate (5 
× 5 mL) and DCM (5 × 5 mL). The solvent was removed in vacuo and the crude 
material was purified by flash chromatography over SiO2 (0 to 10% Methanol in DCM) 
to yield (14.00 mg) as a white solid. The compound was then dissolved into THF (2 ml) 
and iodomethane was added in excess (0.10 mL, 1.60 mmol). The reaction was allowed 
to stir at rt for 20 h. The solvent and excess methyl iodine was removed in vacuo 
resulting in a yellowish solid. Distilled water (10 mL) was added and the reaction and 
was heated to 45°C. Complete solvation of the yellowish material resulted within 
minutes of heating. The reaction was allowed to stir with heating for 3 h, then solvent 
was removed in vacuo. Saturated NaHCO3 aqueous solution (10 mL) was added to the 
reaction mixture, and the product was extracted with DCM (3 × 20 mL). The combined 
organic layers were washed with brine, and dried over Na2SO4. Purification and 
characterization is currently underway. 
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LC-1 (11) 
Known compound 11 was prepared by the method of Neelakantan et al.
234
 Compound 
1a (14.20 mg, 0.05 mmol) was dissolved into ethyl ether (5 mL) and fumaric acid (5.62 
mg, 0.05 mmol) was added. The reaction was allowed to stir for two days and solvent 
was removed in vacuo to yield compound 11 (16.30 mg, 82 %) as a white solid. 
1
H 
NMR (400 MHz, DMSO-d6) δ = 13.00 (s, 2H), 6.62 (s, 2H), 5.22 (dd, J = 11.9, 2.4 Hz, 
1H), 3.97 (t, J = 9.0 Hz, 1H), 2.80 (d, J = 9.0 Hz, 1H), 2.63 (m, 3H), 2.42 – 2.26 (m, 2H) 
2.21 (s, 6H), 2.14 (m, 1H), 2.10 – 1.91 (m, 4H), 1.64 (s, 3H), 1.20 (s, 3H), 1.17 – 1.05 
(m, 2H). Spectral data matches previously reported.
234
  
 
 
Costunolide Fumarate Salt 12 
Compound 1b (15.10 mg, 0.055 mmol) was dissolved into ethyl ether (5 mL) and 
fumaric acid (6.34 mg, 0.06 mmol) was added. The reaction was allowed to stir for two 
days, at which time solvent was removed in vacuo to yield compound 12 (22.20 mg, 
quantitative yield) as an off white solid.  
1
H NMR (400 MHz, DMSO-d6) δ = 6.60 (s, 
2H), 4.78 (dd, J = 10.6, 2.2 Hz, 1H), 4.70 (t, J = 9.7 Hz, 1H), 4.64 (d, J = 10.2 Hz, 1H), 
2.70 – 2.52 (m, 4H), 2.35 – 2.21 (m, 3H), 2.18 (s, 6H), 2.12 – 1.88 (m, 5H), 1.63 (d, J = 
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1.3 Hz, 3H), 1.36 (s, 3H).
 13
C NMR (100 MHz, DMSO-d6) δ = 177.1, 166.2, 139.5, 
136.9, 134.1, 127.5, 126.2, 80.5, 57.0, 50.3, 45.3, 45.2, 44.4, 40.5, 27.1, 25.8, 16.9, 15.9. 
HRMS-ESI
+
 m/z [M+H] Calcd for C17H28NO2 (without salt): 278.2115, found: 
278.2126. 
 
Melampomagnolide B fumarate salt 13 
7a (40.50 mg, 0.15 mmol) was dissolved into DCM (5 mL) and fumaric acid (17.70 mg, 
0.15 mmol) was added. The reaction was allowed to stir overnight, at which time solvent 
was removed in vacuo to yield compound 13 (55.30 mg, 85%) as a white solid. 
1
H NMR 
(400 MHz, DMSO-d6) δ 6.61 (s, 2H), 5.49 (t, J = 7.7 Hz, 1H), 4.01 (t, J = 9.6 Hz, 1H), 
3.92 (q, J = 13.3 Hz, 2H), 2.73 – 2.55 (m, 4H), 2.31-2.14 (m, 10H), 2.13 – 1.99 (m, 3H), 
1.57 (t, J = 10.6 Hz, 1H), 1.47 (s, 3H), 0.96 – 0.86 (m, 1H). 13C NMR (100 MHz, 
DMSO-d6) δ = 177.1, 166.2, 141.0, 134.1, 123.5, 123.4, 80.6, 63.3, 59.9, 57.6, 45.2, 
45.2, 43.4, 42.7, 40.2, 36.9, 25.7, 24.0, 23.0, 17.5. HRMS-ESI
+
 m/z [M+H] calcd for 
C17H28NO4 (without salt): 310.2013, found: 310.2015. 
 
 
2.5.3 Protocol for Mammalian Cell Culture  
All cell lines were maintained in a humidified 5% CO2 environment at 37 °C in 
culture flasks (Corning). Adherent cells were dissociated using 0.25% Trypsin-EDTA 
solution (Gibco). CCRF-CEM cells (ATCC, CCL-119) and NCI/ADR-RES were 
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cultured in RPMI-1640 media (Cellgro) supplemented with 10% fetal bovine serum 
(FBS, Gibco), penicillin (100 I.U./mL), and streptomycin (100 µg/mL, ATCC) at a 
density of 2 × 10
5
 - 2 × 10
6
 cells/mL. DU-145 cells (ATCC, HTB-81), Vero cells 
(ATCC, CCL-81), U-87MG cells (ATCC, HTB-14), and HeLa cells (ATCC, CCL-2) 
were cultured in MEM media (Cellgro) supplemented with 10% FBS (Gibco), penicillin 
(100 I.U./mL), and streptomycin (100 µg/mL, ATCC). HL-60 cells (ATCC, CCL-240) 
were cultured in IMDM media (Cellgro) supplemented with 20% FBS (Gibco), 
penicillin (100 I.U./mL), and streptomycin (100 µg/mL, ATCC). MCF-7 cells (ATCC, 
HTB-22) were cultured in MEM media (Cellgro) supplemented with 10% FBS (Gibco), 
bovine insulin (0.01 mg/mL, Sigma) penicillin (100 I.U./mL), and streptomycin (100 
µg/mL, ATCC). GBM6 cells (gift from the lab of professor John Ohlfest) were cultured 
with DMEM/F12 (1:1) with L-Glutamine, without HEPES (Thermo Scientific) 
supplemented with Normocin (100 µg/mL, Invivogen), 50X B-27 supplement (10 mL, 
Gibco), 100X N-2 supplement (5 mL, Gibco), human EGF (20 ng/µL, Peprotech), 
human FGF-basic (20 ng/µL, PeproTech), penicillin (50 I.U./mL), and streptomycin (50 
µg/mL, ATCC).  
 
2.5.4 Protocol for Cell Culture Cytotoxicity Assays  
The protocol for cellular cytotoxicity assays was previously published by our 
laboratory (Hexum et al).
264
 CCRF-CEM and HL-60 cells were cultured at a density of 
10,000 cells/well in cell culture media (50 µL) in standard 96-well plates (Costar) 24 h 
prior to treatment. DU-145, Vero, U-87MG, GBM6, HeLa, MCF-7, and NCI/ADR-RES 
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cells were seeded at a density of 5,000 cells/well in cell culture media (50 µL) in 
standard 96-well plates (Costar).  Blank (no cells) wells and control (vehicle control 
treated) wells were prepared for every experiment to normalize the data. All PTL 
analogues were serially diluted in pre-warmed media and dosed to 96 well plates (final 
volume/well = 100 µL; final DMSO concentration = 0.5%). Approximately 1-3 h before 
the end of the treatment period (48 h), Alamar Blue (Invitrogen) cell viability reagent 
was added to the 96 well plates (10 µL). A quantitative measure of cell viability can be 
achieved from evaluating the ability of metabolically active cells (which are proportional 
to the number of living cells) to convert resazurin (non-fluorescent dye) to red-
fluorescent resorufin. Fluorescence data were obtained on either a Molecular Devices 
SpectraMax M2 plate reader or an LJL BioSystems HT Analyst plate reader. 
Background fluorescence (no cell controls) was subtracted from each well and cellular 
viability values following compound treatment were normalized to vehicle-only treated 
wells (control wells only treated with aqueous DMSO, which were arbitrarily assigned 
100% viability). Individual IC50 curves were generated by fitting data to the sigmoidal 
(dose response) function of varied slope in GraphPad Prism (v. 5.0) software. Only 
curve fits with R
2
 > 0.95 were deemed sufficient. Each experiment was performed in 
biological triplicate and mean IC50 values were calculated from the individual IC50 
values obtained from each replicate. Standard deviation was calculated from the 
individual IC50 values obtained for each biological replicate. 
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2.6 NMR 
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Chapter 3. Raising the Effective Intracellular Concentration of Parthenolide 
Utilizing a Gold Nanoparticle Delivery System. 
 
3.1 Introduction 
Nanoparticles are particles on the order of nanometers made out of various 
metals (copper, platinum, silver, or gold) or semiconductors (titanium dioxide, cadmium 
selenide, cadmium sulfide, silver sulfide, and lead sulfide).
290
 Ligands are used during 
the synthesis of nanoparticles to control growth and prevent aggregation.
291
 Compared to 
the size of a cell, nanoparticles are up to ten thousand times smaller, around the size of 
receptors, enzymes, and antibodies.
292
 Due to their small size, nanoparticles are capable 
of interactions both extracellular and intracellular.
292
  
Nanoparticles have been intensely investigated as potential drug carriers for 
targeted delivery.
291,293-295
 Nanoparticle delivery systems take advantage of 
pathophysiological alterations observed in tumors, such as increased diffusion and 
permeability due to leaky vasculature of tumors.
296
 Nanoparticles ranging between 20-
100 nm can take advantage of the enhanced permeability and retention  effect (EPR), 
allowing passive diffusion into tumors, thereby permitting greater accumulation when 
compared to free drugs.
297
 Moreover, nanoparticle delivery systems can increase drug 
solubility and allow for timed release of drugs conjugated to them.
298,299
 
However, nanoparticles do have their flaws. The reticuloendothelial system 
(RES) will opsonize large nanoparticles (> 100 nm) and eliminate them through the 
liver.
292,300,301
 To avoid excretion through the RES, smaller particles functionalized with 
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a secondary layer of hydrophilic polymer are used.
301
 Polyethylene glycol (PEG) has 
been widely used to mask nanoparticles from the RES, while also improving water 
solubility.
302
 
Out of all the nanomaterials utilized today, gold nanoparticles (AuNP) have 
become a primary interest in drug delivery research.
295,303,304
 Gold has excellent 
properties that lead to ease of synthesis and functionalization of nanoparticles.
303,305
 
Compared to other materials used, gold has greater chemical stability.
305
 Gold also has 
intrinsic characterization properties that include visible light scattering/absorption, low 
biological concentrations, and large electron density that allows for easy quantification, 
location, and imaging in biological organisms.
305,306
 Additionally, routes have been 
developed for controlled synthesis of AuNP allowing the shape and size of the AuNP to 
be regulated.
307-310
  
AuNPs have been previously loaded with anticancer drugs, such as 
paclitaxel,
301,311
 methotrexate,
312
 daunorubicin,
313
 gemcitabine,
314
 5-fluoruracil,
315
 
cisplatin,
316
 tamoxifen,
317
 trastuzumab,
318
 and doxorubicin.
319
 Agasti et al demonstrated 
that by conjugation to a AuNP delivery system, a 100-fold decrease in the IC50 value of 
5-fluorouracil (5-FU) was observed, from 11.9 µM to 0.7 µM in MCF-7 cells. AuNP in 
this study were used to cage 5-FU, and upon photolysis, 5-FU was released.
315
 
Gold is also readily functionalized by thiols. Utilization of an alkanethiol linker 
to anchor drug payloads to the AuNP is often observed in the literature.
303,320,321
 Thiol 
ligand exchange is a fairly rapid conversion that depends on chain length and 
sterics.
320,322
 Because of these characteristics we have chosen to synthesize parthenolide 
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(PTL) functionalized AuNPs utilizing a PEG-thiol, similar to that of a previously 
reported functionalization of paclitaxel to a AuNP.
311
 By conjugating PTL to a AuNP 
we hope to improve the water solubility of the drug and increase the effective 
concentration delivered to the target cancer cells. 
3.2 Research Objectives 
Current progress on the synthesis and anticancer evaluation of a PTL 
functionalized AuNP is herein reported. We have envisioned three different linkers 
(Figure 3.1) to investigate the effects of conjugating PTL to AuNP: melampomagnolide 
B linker 15, a non-functional linker 16 and a dimethylamino analogue of PTL 
(DMAPT) linker 17. Once synthesized, we will investigate the AuNP’s ability to address 
two major problems with PTL: its poor water solubility and low micromolar anticancer 
activity. A AuNP delivery system should increase the effective concentration of PTL 
delivered to cancer cells allowing detectable levels of PTL, and ultimately reaching the 
IC50 in vivo. Additionally, water solubility of the drug would improve by utilization of a 
PEG linker as well as the innate characteristic of AuNP to improve drug solubility. 
Described here are the efforts made towards the synthesis of a PTL functionalized 
AuNP. 
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Figure 3.1 Proposed linkers for conjugation of PTL to AuNP. Conjugation of PTL via 
ester linker 15, a nonfunctional control linker 16, and a DMAPT inspired linker 17. N 
ranges from 36-55 PEG units CTPEG2000. 
 
3.3 Results and Discussion 
3.3.1 Synthesis of 2 nm Gold Nanoparticles 
2 nm gold nanoparticles were synthesized from a known procedure.
307
 
Tetrachloroaurate trihydrate and p-mercaptophenol were dissolved into methanol. Acetic 
acid was added to the stirring reaction to prevent deprotonation of p-mercaptophenol. 
Next, NaBH4 was added to the reaction gradually, causing a brown precipitate to form, 
which was a clear indication of formation of 2 nm gold nanoparticles. After complete 
addition of NaBH4 the reaction was allowed to stir for 30 minutes then the solvent was 
removed in vacuo. The brown solid was washed with ethyl ether and distilled and 
deionized H2O to remove any excess reagent. Transition electron microscopy was 
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utilized to image the nanoparticles verifying the size of the particles and to observe if 
aggregation had occurred. Particles were found to have an average of 2 nm in diameter 
(Figure 3.2). 
 
 
Figure 3.2 Transition electron microscopy image of synthesized 2 nm gold 
nanoparticles. 
 
 
3.3.2 Solution Phase Functionalization of Gold Nanoparticles 
Originally, use of 2 nm AuNP for conjugation of PTL was planned; however, 
concerns were raised. Two nm AuNP fall short of the requirements for the EPR effect. 
Additionally, TEM images of larger AuNP are easier to resolve. We opted to purchase 
15 nm tannic acid capped AuNP to continue our studies. Tannic acid capped 15 nm 
AuNPs were reacted with the 2,000 mw (Da) carboxyl thiol polyethylene glycol 
(CTPEG2000) at rt for 12 h to yield 18 (Scheme 3.1).  AuNPs were then filtered through 
a 10,000 kDa molecular weight filter to remove excess thiol and tannic acid.  
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Scheme 3.1 Solution phase synthesis of PTL functionalized AuNP. A. Thiol 
functionalization of AuNP. B. Attempted Mitsunobu conditions to synthesize 
Melampomagnolide B (Mel B) functionalized AuNP. C. Attempted synthesis of non-
functional AuNP.  
After resuspension of the AuNP 18 in Millipore water, UV-Vis full spectrum 
analysis was performed. We observed that functionalization of the AuNP via ligand 
exchange of the thiol for tannic acid had occurred due to an observed reduction in the 
wavelength max (520 nm) of 15 nm AuNPs (Figure 3.3).
306
 Additionally, we could 
confirm a 15 nm core particle size (Figure 3.4). 
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Figure 3.3 Full spectrum UV-Vis absorption of functionalized 18 and non-
functionalized gold nanoparticles. A reduction of absorbance at the wavelength max of 
15 nm AuNP (λ = 520 nm) was observed upon functionalizing with thiols. 
 
 
 
Figure 3.4 Transition electron microscopy image of 15 nm AuNP after funtionalization 
with carboxyl thiol PEG 18. Core particle size was 15 nm. 
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Following the protocol to conjugate paclitaxel to a AuNP, Mitsunobu conditions 
were performed to conjugate melampomagnolide B (7) to 18 (Scheme 3.1).
311
 DMF was 
added to the solution of 18, and the water was removed in vacuo.  4-(N,N-
Dimethylamino)pyridinium-4-toluenesulfonate and N,N’-diisopropylcarbodiimide was 
added to the reaction and left to stir overnight. Irreversbile Aggregation of the AuNP 
was observed the next day. 
In an effort to synthesize the non-functional AuNP, peptide coupling conditions 
were performed to conjugate 3-(dimethylamino)-1-propylamine to the free carboxylic 
acid of 18. PyBOP and dimethylamine were reacted with 18 overnight. Aggregation of 
the AuNP was observed similar to that observed with coupling to melampomagnolide B. 
Based on these unexpected difficulties, it was decided to first synthesize the PTL-linker-
thiol reagent, and then couple the pre-assembled payload to the nanoparticle. 
 
3.3.3 Solid Phase Synthesis of DMAPT Linker for Gold Nanoparticle 
Functionalization 
In an effort to avoid the aggregation issues of solution phase synthesis of the 
PTL functionalized linker on a AuNP, solid phase synthesis was performed. FMOC 
protected Rink amide MHBA resin was deprotected with piperidine. After washing the 
resin with DMF, it was reacted with mercaptoacetic acid in the presence of EDCI and 
TEA to yield the free thiol on resin (Scheme 3.1).  
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Scheme 3.2 Solid phase synthesis of dimethylamino analogue of PTL (DMAPT) PEG 
linker 17. N ranges from 36-55 PEG units CTPEG2000. 
 
Any disulfide bonds formed from the free thiol of mercaptoacetic acid were then 
cleaved with DTT. Rigourous washing to remove the DTT was performed and the 
resulting free thiol was reacted with the 2000 MW thiol carboxyl PEG (CTPEG2000) 
yielding compound 21. In an effort to prevent linkers on resin to react with each other 
during peptide synthesis with N,N-dimethyl-1,3-propanediamine, the diamine was 
monofunctionalized beforehand with PTL in a Michael addition to yield compound 22 
in 98% yield. Current effort are  focused on exploring peptide coupling reagents to 
conjugate 22 to 21, and then cleaving 23 from resin to yield the DMAPT linker 17. 
 
3.4 Conclusion and Future Direction 
In summary, we have attempted to synthesize a PTL functionalized AuNP. 
Initial solution phase synthetic routes lead to irreversible aggregation of the AuNP via 
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Mitsunobu and peptide coupling reactions. Functionalization of the AuNP with 
CTPEG2000 was achieved by a thiol exchange reaction to replace the tannic acid capping 
the AuNP. To circumvent the observed aggregation, we have begun solid phase 
synthesis of the PTL functionalized linkers. Once synthesized, we will react the linkers 
with tannic acid capped AuNP for a facile thiol exchange reaction. Anticancer activity of 
the PTL functionalized AuNP will be evaluated in vitro upon completion of the 
synthesis.  
 
3.5 Experimental 
  Parthenolide was purchased from Enzo Life Sciences. Commercial grade 
reagents (Aldrich, Acros, Alfa Aesar) were used without further purification unless 
otherwise noted.  15 nm gold nanoparticles were purchased from Ted Pella Inc 
(Redding, CA). Carboxyl thiol polyethylene glycol (mw = 2000) was purchased from 
JenKem Technology USA (Allen, TX). Centrifuge filters were purchased from Millipore 
(Billerica, MA). 2 nm Transition electron microscopy images were peformed by the 
UMN characterization facilty on a on a Tecnai G
2
 F30 microscope. 15 nm AuNP 
Transition electron microscopy images were also performed by the UMN 
characterization facility on a Tecnai T12 microscope. UV-Vis full specrum analysis was 
performed on a Molecular Devices SpectraMax M2 plate reader using millipore water as 
a solvent Nuclear magnetic resonance (NMR) spectroscopy employed a Bruker Avance 
instrument operating at 400 MHz (for 
1
H) and 100 MHz (for 
13
C) at ambient 
temperature. Internal solvent peaks were referenced in each case. 
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  3.5.1 Synthesis of 2nm Gold Nanoparticles 
Two nm gold nanoparticles were synthesized from the Brust method.
307
 
Tetrachloroauric(III) acid (298.5 mg, 0.88 mmol) and p-mercaptophenol (230 mg, 1.82 
mmol) were dissolved into 150 mL of MeOH. AcOH (3 mL) was then added. NaBH4 
(30 mL, 0.4 M) was added slowly (1 mL every 30 seconds) affording a brown ppt. 
Reaction was then allowed to stir for 30 minutes after complete addition of NaBH4. 
Solvent was then removed in vacuo and the remaining brown solid was washed with 
ethyl ether (20 mL) and then deionized water (20 mL) to yield a brown solid (1.26 g). 
Transition electron microscopy images showed an average size of 2 nm of the particles 
(Figure 3.2). 
 
3.5.2 Synthesis of Parthenolide Functionalized Gold Nanoparticles in Solution. 
Synthesis of CTPEG2000 Functionalized AuNP (18) 
A 15 nm tannic acid-capped gold nanoparticle solution in distilled and deionized 
water (2mL, 1.1x10
12
 particles/mL) was reacted with a non-discrete CTPEG2000 (50.0 
mg, 0.03 mmol) overnight. The next day, the reaction was filtered through a 10,000 mw 
centrifuge filter, washed with distilled and deionized water (3 x 0.5 mL) through the 
centrifuge filter. Remaining nanoparticle solution that did not filter was removed from 
the centrifuge filter and resuspended into distilled and deionized water (total volume of 
2 mL). A total volue of 2 mL was required to be compare the UV-Vis spectrum of the 
functionalized AuNP to the starting tannic acid-capped AuNP. Full spectrum UV-Vis 
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was performed to gauge functionalization. 
1
H NMR (400 MHz, D2O) δ = 3.71 (s, 189H) 
2.74 (t, J = 6.3 Hz, 2 H, -CH2-SH). 189 protons correlates to 47 repeat PEG units, which 
falls into the range of PEG repeat units observed by maldi of CTPEG2000 starting 
material. 
 
3.5.3 Solid Phase Synthesis of DMAPT Linker 17 
 
Synthesis of 21. 
Rink amide MHBA resin (21.4 mg) was swelled in DMF (1 mL) for 10 minutes 
in a solid phase reaction vessel. Piperidine (0.2 mL, 0.002 mmol) was added and 
allowed to shake for 1 h. The reaction was filtered and washed with DMF (5 x 1 mL) 
with manual shaking between washes. Kaiser test verified deprotection of the amine was 
achieved. The resin was swelled with DMF (1 mL) for 10 minutes. Mercaptoacetic acid 
(0.01 mL, 0.14 mmol), EDCI (24.3 mg, 0.16 mmol), and Et3N (0.02 mL, 0.14 mmol) 
were added to the reaction vessel and left to shake over night. Reaction was filtered and 
washed with DMF (5 x 1 mL) with manual shaking between washes to form the amide 
bond on resin.  
The resin was then swelled with DMF (1 mL) for 10 minutes. Dithiothreitol 
(28.5 mg, 0.19 mmol) was added and reaction was allowed to shake for 15 minutes. 
Reaction was filtered and washed with DMF (5 x 1 mL) with manual shaking between 
washes. The resin was reswelled with DMF (1 mL) for 10 minutes, and CTPEG2000 
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(23.4 mg, 0.0117 mmol) was added to the reaction vessel and left to shake over night. 
Next day reaction was filtered and washed with DMF (5 x 1 mL) with manual shaking 
between washes to yield compound 21. Future direction would involve peptide coupling 
with 22 to anchor PTL to resin.  Cleavage of the disulfide bond would then yield the 
DMAPT Linker which can be functionalized to a gold nanoparticle. 
 
 
Dimethyl-Propanediamine Parthenolide 22 
Parthenolide (32.6 mg, 0.13 mmol) as dissolved into MeOH (5 mL) and an 
excess of N,N’-Dimethyl-1,3-propanediamine (0.1 mL, 0.80 mmol) was added and the 
reaction was allowed to stir overnight at rt. The next day solvent and excess N,N’-
Dimethyl-1,3-propanediamine was removed in vacuo to yield compound 23 (45.2 mg, 
98%) as a clear oil. 
1
H NMR (400 MHz, CDCl3) δ = 5.17 (d, J = 11.5 Hz, H), 3.79 (t, J 
= 9.0 Hz, 1H), 2.77 (dd, J = 13.4, 4.8 Hz, 1H), 2.69 (m, 2H), 2.60 (t, J = 6.9 Hz, 2H), 
2.45 – 2.32 (m, 7H), 2.26 (m, 2H), 2.20 (s, 3H), 2.16 – 2.01 (m, 5H), 1.67 (s, 3H), 1.63 
(m, 2H), 1.27 (s, 3H), 1.20 (td, J = 13.0, 5.6 Hz, 1H). 
13
C NMR (100 MHz, CDCl3) δ = 
176.6, 134.7, 125.2, 125.1, 82.2, 66.7, 61.4, 57.0, 56.5, 50.5, 48.0, 46.6, 42.7, 41.3, 36.8, 
30.1, 27.7, 24.2, 17.1. MS-ESI
+
 m/z calcd for C20H35N2O3: 351.2648, found: 351.2611. 
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